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ABSTRACT 
 Background: Recent research indicates that obesity may exacerbate certain symptoms 
of Multiple Sclerosis (MS). Nevertheless, little research has examined patients’ perceptions 
of how obesity may impact their MS symptoms. If MS patients are unaware of the 
relationship between obesity and MS symptoms, they may be less motivated and/or adherent 
to health behaviors that could reduce their symptoms.  
 Aims: (1) To determine whether functional differences exist between healthy weight 
and overweight/obese MS patients; (2) To examine patient beliefs about the impact of health 
behaviors on MS; (3)To explore MS patient beliefs regarding the impact of weight on 
symptom severity ; and (4) To explore the amount of exercise patients with MS would be 
willing to engage in to reduce their MS symptoms.   
 Methods: 81 MS patients completed neuropsychiatric tests and questionnaires. 
Height, weight, and waist circumference were measured to calculate body mass index (BMI) 
and waist-to-height ratio (WTHR). Participants completed novel measures designed to assess 
their beliefs regarding how weight gain or loss may impact their MS symptoms, and their 
willingness to exercise for symptom improvement.  
 Results: There was a significant association between WTHR and depression. There 
was no association between WTHR and the composite measures of cognition, physical 
function, or a singular measure of anxiety. As a whole, patients endorsed the belief that 
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excess body weight contributes to worse MS symptoms and progression. Patients reported 
logical increases in exercise willingness as the percentage of hypothetical improvement 
increased. Patients with higher current symptom severity reported increased willingness to 
exercise for higher levels of symptom improvement relative to patients with lower current 
symptom severity.  
 Discussion: This was the first study to examine patient beliefs about the impact of 
weight on disease symptoms and how much patients are willing to exercise to improve their 
symptoms. Results showed that patients with MS believe that excess body weight negatively 
influences disease symptoms. Furthermore, patients reported increased willingness to 
exercise as the percentage of proposed symptom improvement increases. This suggests that 
providing patients with information on the amount of improvement to expect from exercise 
and dietary interventions may enhance motivation for health behavior change.  
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CHAPTER 1 
REVIEW OF THE LITERATURE 
 Historically, medicine relied upon biological explanations of disease(Deep, 1999), 
which assume that pathology is due to a specific etiology, such as a virus or bacteria. 
Clinicians and researchers were challenged in the late 1970s to incorporate environmental, 
social, and behavioral factors into their conceptualization of disease(Engel, 1977). Since that 
time, the biological model of disease has shifted toward a more integrated approach, often 
referred to as the biopsychosocial model(Engel, 2012). This shift has opened the door for 
greater exploration of the multi-factorial causes of disease. In particular, scientific 
understanding of idiopathic diseases has improved as greater efforts are made to examine 
epigenetic factors that incite disease as well as social or environmental factors that 
exacerbate disease activity(Engel, 2012).  
Multiple sclerosis (MS) is the most common neurodegenerative illness among young 
adults(Steinman, 2009), yet, it is an enigmatic condition. Many of the risk factors for the 
disease are known, but researchers cannot accurately predict its progression(Ascherio, 2013; 
Ascherio & Munger, 2007a, 2007b, 2010; Ascherio et al., 2014; Munger, Chitnis, & 
Ascherio, 2009). Recent research has highlighted a potential link between obesity and 
increased risk for MS or worsened disease course and symptoms via the hormone 
leptin(Matarese, Carrieri, Montella, De Rosa, & La Cava, 2010; Matarese, Procaccini, & De 
Rosa, 2008). Examination of the impact of obesity on disability in MS may illuminate 
important behavioral factors that can be addressed to improve physical, emotional, and 
cognitive symptoms among MS patients. Moreover, a better understanding of how patients 
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perceive obesity contributing to their symptoms may be useful when developing diet and 
exercise interventions that require ongoing adherence.    
The following literature review will first serve as an introduction to the etiology, 
symptoms, and patient beliefs of MS. Next, we will examine obesity and discuss research 
linking MS and obesity via immunoregulatory and hormonal mechanisms.  
    Multiple Sclerosis 
MS is an autoimmune/neurological disease that attacks portions of the central nervous 
system (CNS) leading to inflammation and destruction of the myelin sheath on 
neurons(Sospedra & Martin, 2005). Damage to the myelin sheath disrupts communication 
within the brain, and between the brain and the rest of the body(Corthals, 2011). Symptoms 
caused by this disruption are variable and can include: tingling, numbness, weakness, and 
problems with coordination, balance, vision, speech, memory, cognitive processing, decision 
making, mood stability, and lack of energy. At least 400,000 individuals in the United States 
alone have MS, and more than 2.5 million people are believed to have MS worldwide(Braley 
& Chervin, 2010).  
Disease Characteristics 
Obesity as a potential risk factor for developing MS 
Children who are overweight prior to the age of 20 have a two-fold increased risk of 
developing MS in comparison to their healthy weight counterparts(Langer-Gould, Brara, 
Beaber, & Koebnick, 2013; Munger et al., 2013).  Risk of MS has been shown to increase by 
1.61-1.95 fold for 7-13 year old girls who are ≥ 95th percentile of BMI when compared to 
those below the 85
th
 percentile(Munger et al., 2013).  Research in the US and Europe has 
indicated that obesity in late adolescence/early adulthood may be especially dangerous as an 
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obese weight status at age 18 is associated with a 71 percent increased risk of MS(Munger et 
al., 2009). Some research indicates that the link between obesity and increased risk of MS 
may be especially pronounced in females(Hedström, Olsson, & Alfredsson, 2012; Munger et 
al., 2009). Females typically have a higher percentage of body fat than males(Blaak, 2001) 
and thus, increased weight, along with hormonal differences between men and women, may 
account for differential prevalence rates among genders(Sospedra & Martin, 2005). This is 
further supported by studies which show that MS disease activity wanes during pregnancy, 
but worsens during a woman’s menstrual cycle, following pregnancy, and when estradiol 
levels are high but progesterone levels are low(Wingerchuk & Rodriguez, 2006; Zorgdrager 
& De Keyser, 1997, 2002).   
Gender Differences 
 Women are diagnosed with MS at rates two to four times higher than men, 
depending upon the region of the world in which they live. Current estimates show that in 
northern latitudes as many as 4.55 women are affected for every man. In Canada the ratio of 
women-to-men afflicted with MS is 3.2:1, some areas of Europe have ratios as high as 
3.77:1, and the overall worldwide ratio was 2.6:1 in the year 2000(Alonso & Hernán, 2008; 
Boström, Stawiarz, & Landtblom, 2013; Ramagopalan et al., 2010; Trojano et al., 2012). 
Researchers speculate that women who live in extreme latitudes are less frequently exposed 
to the sun and that their cosmetic makeup with UV protection further prevents exposure to 
sunlight and consequently decreases vitamin D levels(Corthals, 2011).  
Potential Environmental Contributors to MS  
A strong inverse relationship has been shown between sunlight exposure and the 
incidence of MS (r= -.80)(Acheson, Bachrach, & Wright, 1960). Researchers believe that 
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sunlight and therefore vitamin D, exerts protective effects on individuals at risk for 
MS(Ascherio, 2013). Supporting this assertion, the hormonal form of vitamin D3, 1,25-
dihydroxyvitamin D3, can prevent the mouse model of MS known as experimental 
autoimmune encephalomyelitis (EAE)(Hayes, Cantorna, & DeLuca, 1997). The hormonal 
form of vitamin D3 is believed to possess immunoregulatory effects that protect against MS 
and may reduce MS symptoms following vitamin D supplementation(Correale, Ysrraelit, & 
Gaitán, 2009). 
The geographical based incidence of MS may also be explained by factors besides 
vitamin D. Countries located further from the equator are predominantly more wealthy and 
westernized and possess drastically different lifestyles than other under-developed 
countries(Cantorna, 2008). Differences in hygiene and dietary standards between westernized 
and undeveloped countries may contribute to increased risk of MS. An ongoing case-control 
study of environmental factors associated with pediatric MS found that pediatric MS patients 
consumed lower daily levels of fiber, iron, and dairy relative to controls(Pakpoor et al., 
2016). Furthermore, low iron intake was significantly associated with an increased risk for 
MS(Pakpoor et al., 2016). However, groups did not differ in their daily consumption of 
sodium, fats, proteins, carbohydrates, sugars, fruits and vegetables(McDonald et al., 2016; 
Pakpoor et al., 2016). Indeed, the relationship between food intake and immune function and 
risk for MS warrants further study.  
The hygiene hypothesis is an alternate explanation of the geographical incidence of 
MS. It suggests that natural, uninhibited exposure to disease is protective and allows for 
proper immune response development(Sotgiu, Angius, Embry, Rosati, & Musumeci, 2008). 
Individuals who live in westernized societies (i.e. many of which are located further from the 
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equator) are not exposed to the kinds of infections and diseases that those in under-developed 
societies are(Cantorna, 2008). Increased cleanliness, sanitation, and vaccinations may 
prevent the body from learning how to appropriately regulate immune function. This 
hypothesis has been supported by studies which demonstrate that animals exposed to worm 
infections are not susceptible to EAE and that societies experience an upsurge in MS 
following increased sanitation and eradication of diseases, such as malaria(Cantorna, 2008; 
Sotgiu et al., 2008).  
Significant differences in diet are also found between Western and developing 
countries.  The western diet is packed with foods that are scarcely eaten in developing 
countries. High levels of sugar, processed carbohydrates, animal fat, red meat, and fried food 
combined with low fiber and vegetable intake characterize the western diet(Riccio & 
Rossano, 2015). Long term dietary habits have been shown to significantly affect cellular 
function and gut microbiota(Riccio & Rossano, 2015). The gut contains between 70 and 80 
percent of the body’s immune cells and is considered to be the largest immune organ in the 
body(Vighi, Marcucci, Sensi, Di Cara, & Frati, 2008). Recently, gut system microbiota have 
been shown to influence extraintestinal biological and immunological functions such as 
human nutrition, metabolism, and immune-system function(Chassaing & Gewirtz, 2014; 
Chassaing et al., 2015; Riccio & Rossano, 2015; Vighi et al., 2008). Dietary factors may 
induce catabolism or anabolism by altering cell metabolism through interaction with 
transcription factors, enzymes, and nuclear receptors(Desvergne, Michalik, & Wahli, 2006). 
This may prompt unnecessary degradation or production of proinflammatory cytokines and 
could possibly mediate disease activity(Chassaing et al., 2015; Desvergne et al., 2006). In 
addition, research has shown that gut microbiota affect neurological inflammation in EAE by 
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altering the pro-inflammatory and anti-inflammatory immune response(Y. K. Lee, Menezes, 
Umesaki, & Mazmanian, 2011). Although diet is unlikely the sole causative factor of MS, it 
may be an important component that helps to explain, at least in part, the vast geographical 
differences in incidence.  
Diagnosis and Treatment of MS 
Patients are typically diagnosed with MS following acute episodes of neurological 
dysfunction that may be characterized by numbness, tingling, balance problems, dizziness, 
poor bladder control, spasticity, optic neuritis and/or blurred vision(Confavreux, Vukusic, 
Moreau, & Adeleine, 2000). MS symptoms may indicate any of several conditions. 
Clinicians must rule out other potential conditions prior to making a diagnosis of MS since 
there is no single test that will confirm a diagnosis of MS.   
Currently, the McDonald criteria for MS are held as the gold-standard guidelines for 
confirmation of MS(Polman et al., 2011). According to these standards, clinicians must 
obtain objective evidence of lesions in the central nervous system (CNS) that are 
disseminated in time and space. Dissemination in time requires that patients experience at 
least two attacks (episodes of neurological dysfunction that last a minimum of 24 hours), that 
are at least 30 days apart so that distinct neurological events can be confirmed. Dissemination 
in space requires that patients express at least two lesions in two separate areas of the CNS.  
Magnetic resonance imaging (MRI) is used to detect lesions, but cerebrospinal fluid (CSF) 
and visual evoked potentials are also examined to help support a diagnosis in cases where the 
clinical or MRI data are inconclusive. MS is most typically diagnosed in patients aged 20-50, 
with an average age of onset at 34(McFarlin & McFarland, 1982a, 1982b). The majority of 
patients (≥80 percent) are initially diagnosed with a relapsing-remitting subtype of MS 
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(RRMS), which is characterized by recurrent periods of disease activity followed by a return 
to normal or nearly normal functioning(Confavreux et al., 2000). MS is a progressive disease 
and most patients who have RRMS eventually develop a secondary progressive 
course(Confavreux et al., 2000). Secondary progressive MS (SPMS) is characterized by 
insidious decline in neurologic function. Patients may still experience exacerbations with 
some remittance; however gradual decline replaces the stability seen in RRMS between 
relapses. MS patients can typically expect to experience greater disability the longer they 
have the disease. In addition, while men are diagnosed less often than women overall, they 
are more likely to be diagnosed with primary progressive MS (PPMS)(Miller & Leary, 
2007). PPMS is a more aggressive MS subtype that is characterized by unremitting 
neurological and physical decline.  
Though there is no cure for MS, pharmacotherapies are available that slow disease 
progression, reduce exacerbation severity, decrease the formation of new brain lesions, and 
reduce exacerbation frequency. Several FDA approved injection-based and oral medications 
are currently available for the treatment of RRMS(Corboy, Goodin, & Frohman, 2003). 
Symptom-specific medications are also available, and are effectively used to help patients 
manage the disease on a day-to-day basis and improve quality of life. Finally, psychotherapy, 
physical therapy, and occupational therapy are frequently used to treat resulting emotional, 
physical, and cognitive difficulties (Solari et al., 1999; Steultjens et al., 2003; van Kessel et 
al., 2008). 
Physical Functioning in MS  
MS patients endure a wide array of physical symptoms. Damage to the brain’s grey 
matter, myelin and axons in different areas of the brain produces a variety of symptoms 
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throughout the body that range from mildly annoying to severely debilitating. These 
symptoms are often associated with neurologic disease processes, but are also commonly 
found among patients with obesity. It is possible that the common MS symptoms described 
below are exacerbated by the comorbid presence of obesity(Matarese et al., 2008). 
Mobility 
Mobility is often problematic for MS patients due to symptoms which impede the 
body’s ability to move fluidly, safely, and effectively. Spasticity, unstable balance, and 
muscle weakness commonly interfere with walking, exercise, employment, and daily living 
activities(Hobart, Riazi, Lamping, Fitzpatrick, & Thompson, 2003; Martin et al., 2006; 
Messier, 2008; Messier et al., 1994; Rizzo, Hadjimichael, Preiningerova, & Vollmer, 2004).  
Spasticity 
 MS patients experience spasticity which includes muscle spasms, feelings of stiffness 
or tightness, and difficulty initiating and/or controlling muscle movement(Rizzo et al., 2004). 
Spasticity most often occurs in the legs and manifests in two forms: flexor spasticity and 
extensor spasticity. Flexor spasticity involves the hamstrings and hip flexors and is 
characterized by bent knees and hips that are difficult to straighten. Extensor spasticity 
involves the quadriceps and adductors and is characterized by straight hips and knees and 
legs that remain extremely close together and may cross over at the ankles. Spasticity occurs 
due to imbalanced inhibitory and excitatory neuro-muscular input leading to hyperactivity in 
the muscles. 67 percent of MS patients experience  minimal to moderate spasticity while 13 
percent report severe spasticity(Rizzo et al., 2004). At least one-third of MS patients report 
that they must modify or remove certain daily activities due to their spasticity(Rizzo et al., 
2004).  
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Balance 
Poor balance and gait dysfunction in MS patients is evidenced during the gait cycle in 
temporal-spatial gait parameters of velocity, cadence, double limb support, and stride 
length(Hobart et al., 2003). MS patients walk at reduced speeds, with shorter stride length 
and increased double limb support compared to patients without MS(Martin et al., 2006). 
These aberrations in movement are considered to be indicators of instability. In particular, 
these temporal-spatial gait parameters have been associated with worse balance(Winter, 
Patla, & Frank, 1990). Other indicators of malfunction include knee and ankle kinematics, 
and aberrant tibialis anterior and medial gastrocnemius activity.  Restricted ankle range of 
motion that is not attributable to reduced walking speed has been found in MS patients. 
Additionally, MS patients show aberrations in timing and amplitude of tibialis anterior and 
medial gastrocnemius throughout the duration of a stride(Martin et al., 2006). This 
combination of factors is a marker of compromised walking stability that hinders general 
mobility among MS patients. Mobility loss can be one of the most disabling symptoms of 
MS. Reduced mobility is related to loss of independence, loss of employment, increased need 
for caregivers, and reduced quality of life(Dunn, 2010). Decreased mobility may also 
exacerbate other symptoms associated with MS such as bowel/bladder problems, edema, 
numbness and tingling, muscle tightness/weakness, and decreased heart and lung 
function(Motl, 2014).  
Weakness  
Many MS patients experience muscle weakness. Complaints of a foot dragging or the 
feeling that one’s arms or legs feel “heavy” are common in MS. Weakness may be due to 
deconditioning from mobility impairments related to pain, fatigue, gait problems, poor 
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balance, or reduced muscle activity(Dalgas, Stenager, & Ingemann-Hansen, 2008). Weakness 
may also result from neurological degradation caused by disease activity. Damage to nerve 
fibers may impede the communication of neuroelectrical signals from the brain to the muscle 
and decrease strength. Clinicians and researchers highlight continued movement and exercise 
as a preventative mechanism for maintained muscular strength, with the understanding that 
reduced physical activity may lead to increased weakness, pain, and movement 
difficulty(Dalgas & Stenager, 2012; Dalgas et al., 2008).  
 Fatigue 
 Fatigue has been labeled the most common and most debilitating symptom of 
MS(Induruwa, Constantinescu, & Gran, 2012). It has been defined as ‘‘a subjective lack of 
physical or mental energy that is perceived by the individual or caregiver to interfere with 
activities of daily living(Kos, Kerckhofs, Nagels, D'hooghe, & Ilsbroukx, 2008).” Fatigue 
may be primary (i.e. caused by disease activity) or secondary (i.e. stemming from conditions 
related to the disease such as sleep disturbance, pain, spasms, etc.). Up to 90 percent of MS 
patients report problems with fatigue(Fisk, Pontefract, Ritvo, Archibald, & Murray, 1994; 
Vucic, Burke, & Kiernan, 2010) which results in significant cost to patient productivity, 
employment, activities of daily living and overall quality of life(Braley & Chervin, 2010). 
Because fatigue is considered the most “debilitating” component of MS, it warrants more in-
depth exploration. Controllable factors, such as carrying excess body weight, may be linked 
to added fatigue in MS and require more study.  MS clinicians/researchers discuss two forms 
of fatigue, cognitive and physical, separately. 
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Cognitive Fatigue  
 Cognitive fatigue is defined as a “psychobiological state caused by prolonged periods 
of demanding cognitive activity (Marcora, Staiano, & Manning, 2009).” It has been 
positively associated with destruction of neural tissue. MRI and PET studies have shown that 
grey matter pathology of the cerebral cortex and deep structures (e.g. thalamus; caudate of 
basal ganglia) is associated with increased fatigue in MS
61
. Atrophy of the parietal cortex has 
also been associated with fatigue(Pellicano et al., 2010). Damage to axons results in reduced 
connectivity among neurons in the central nervous system. The ratio of N-acetylaspartate 
(NAA) to creatine is used as a proxy for axonal damage. Findings from proton magnetic 
resonance spectroscopy indicate that lower levels of NAA in proportion to creatine is 
associated with greater fatigue in MS patients(De Stefano et al., 2001; Tartaglia et al., 2004). 
These results support the theory that patients with axonal damage must recruit additional 
neural pathways and cortical areas to complete tasks. This increased expenditure of neuronal 
energy is believed to underlie the experience of cognitive fatigue and excessive effort 
required to complete activities(Induruwa et al., 2012). 
 Aberrations in neural activity within the frontal lobes, thalamus, and basal ganglia 
have also been postulated to underlie cognitive fatigue (Chaudhuri & Behan, 2000). fMRI 
studies have shown increased activation in basal ganglia, frontal areas including superior, 
medial, middle and inferior regions, parietal regions (precuneus and cuneus), thalamus, 
cingulate motor area, and  anterior cingulate(DeLuca, Genova, Hillary, & Wylie, 2008). This 
increased activation is believed to indicate the need for increased effort in the presence of 
fatigue. Conversely, other studies have found significant deactivations in regions associated 
with movement and motor planning/execution (Filippi et al., 2002). Importantly for this 
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project, research has indicated that the experience of cognitive fatigue intensifies both the 
perception of physical fatigue as well as reduced physical performance. Patients with 
cognitive fatigue experience exhaustion from exercise sooner and report greater effort output 
compared to patients who are not cognitively fatigued(Marcora et al., 2009). This suggests a 
crucial relationship between cognitive and physical fatigue may exist, such that the 
experience of one increases the likelihood of the other and may create a cycle that 
perpetuates sedentary and unhealthy behaviors. 
Physical Fatigue 
 Pro-inflammatory cytokines (e.g. Interferon-γ (IFN- γ), tumor necrosis factor-α 
(TNF- α), and interleukin 1, 6, and 10) are believed to contribute to physical fatigue in MS.  
MS patients display higher levels of IFN- γ, TNF- α, and interleukin-6 than non-fatigued MS 
patients(Braley & Chervin, 2010; Induruwa et al., 2012).  The endocrine system may play a 
role in MS-related fatigue. Increased reactivity of the hypothalamo-pituitary-adrenal (HPA) 
axis, higher levels of adrenocorticotropic hormone (ACTH) and lower levels of 
dehydroepiandrosterone (DHEA) have been demonstrated in MS patients with fatigue when 
compared to those without fatigue(Gottschalk et al., 2005; Téllez et al., 2006). MS patients 
often report feeling less fatigue while on corticosteroids. Corticosteroids mimic hormones 
and reduce inflammation when given in high doses. Researchers believe that the hormonal 
mechanism of action by corticosteroids further supports a potential endocrine role in the 
development of fatigue(Braley & Chervin, 2010).   
Emotional Functioning in MS  
MS patients experience depression and anxiety at higher rates than in the general 
population and even compared to patients with other chronic conditions(Siegert & 
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Abernethy, 2005). The lifetime prevalence for depression in MS is 50 percent, with a point 
prevalence of 20 percent(Siegert & Abernethy, 2005).
 
Most patients with MS develop 
depression and anxiety after the onset of their disease, which suggests that biosocial factors 
of MS may be causal to the development of psychological problems(Feinstein, Magalhaes, 
Richard, Audet, & Moore, 2014; Ron & Logsdail, 1989).  
Depression and anxiety have been shown to increase both morbidity and mortality 
among MS patients. Comorbid anxiety and depression have been associated with greater 
somatic complaints, social difficulties, decreased quality of life, and increased thoughts of 
suicide(Brown et al., 2009; Feinstein et al., 2014). Research on suicide indicates that the 
proportion of suicides among MS patients is higher (in one study up to 7.5 times 
higher(Sadovnick, Eisen, Ebers, & Paty, 1991)) than in the age-matched general 
population(Siegert & Abernethy, 2005). Another study with the Danish National Registry of 
Cause of Death found that 25 percent more MS patients died by suicide over a 32 year period 
than would be expected for an age adjusted group of that size(Stenager et al., 1992).  
Genetic, immunologic, biochemical, and psychosocial factors are known contributors 
to psychiatric difficulties in MS, but recent research indicates that neurological and structural 
changes due to MS account for the most  variance (42 percent) in MS depression(Feinstein et 
al., 2014). MRI studies have shown that hypointense lesions in superior frontal and superior 
parietal regions, along with atrophy in the frontal lobes and enlarged third and lateral 
ventricles are related to the development of depression in MS(Bakshi, Czarnecki, et al., 
2000). Another study found that hyperintense lesions in medial inferior frontal regions along 
with atrophy in dominant anterior temporal areas was associated with depression in 
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MS(Feinstein et al., 2004). These findings highlight the importance of brain atrophy in the 
pathogenesis of MS-related depression.  
Hyperactivation in the HPA axis in combination with high levels of cortisol, ACTH, 
DHEA-sulfate have also been linked to depression in MS(Fassbender et al., 1998). 
Dysfunction in the immune system has been recently theorized to underscore depression in 
MS. Increased circulating levels of proinflammatory cytokines (TNF, IL-1, IL-6) activate the 
HPA axis and can cause the high levels of ACTH and DHEA-sulfate described above(Gold 
& Irwin, 2009; Sukoff Rizzo et al., 2012). Researchers speculate that proinflammatory 
cytokines cause depression by reducing levels of serotonin released into the synapse(Kim et 
al., 2007). This reduction in serotonergic function may also disrupt noradrenergic and 
serotonergic systems that antidepressants are designed to modulate(Craddock & Thomas, 
2006).  
Antidepressant medications are frequently used to treat depression in MS and 
research has shown their effects to be approximately equivalent to those seen in the general 
population with depression(Feinstein et al., 2014; Feinstein, O'Connor, Gray, & Feinstein, 
1999). Another treatment, cognitive behavioral therapy, has been shown to improve 
depression and anxiety among MS patients when used in isolation or in combination with 
psychotropic medications(Feinstein et al., 2014). Research on exercise for the treatment of 
depression and anxiety in MS is currently being conducted and may provide benefits that 
extend beyond neuropsychiatric improvement into the domains of quality of life, physical 
health, and cognitive function(Padgett & Kasser, 2013)  
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Cognitive Functioning in MS  
Cognitive impairment afflicts between 40 and 60 percent of MS patients(Feinstein et 
al., 2014). Increasing cognitive impairment is associated with disease progression such that 
patients in later stages of the disease (SPMS versus RRMS) typically experience the most 
severe cognitive dysfunction. Commonly observed cognitive difficulties include problems 
with memory, processing speed, attention, executive control, and impulsivity(Riccitelli et al., 
2011; Tinnefeld et al., 2005). These cognitive difficulties are, in turn, associated with 
impairment in one’s ability to maintain employment, complete everyday tasks, sustain 
meaningful relationships, and plan effectively for future events(Chiaravalloti & DeLuca, 
2008) 
Processing speed 
 Up to 50 percent of MS patients experience reduced information processing 
speed(DeLuca, Chelune, Tulsky, Lengenfelder, & Chiaravalloti, 2004). Impairment is 
common on tasks like the symbol digit modalities test and paced auditory serial addition task 
(PASAT)(Paul, Beatty, Schneider, Blanco, & Hames, 1998). However, when time to process 
information is removed, RRMS patients show accurate performance on tasks that assess 
learning and memory(DeLuca et al., 2004; Demaree, DeLuca, Gaudino, & Diamond, 1999). 
This indicates that the basic ability to process, encode, and manipulate information is still 
intact among most RRMS patients. For this reason, information processing speed is 
frequently considered the primary cognitive deficit in RRMS. Eventually, information 
processing deficits reach a critical level in which other abilities (e.g. working memory) are 
impaired beyond what can be explained by deficient processing speed(Chiaravalloti & 
DeLuca, 2008; DeLuca et al., 2004; Demaree et al., 1999).  
  
16 
 
Memory  
Impaired memory is one of the most cited cognitive complaints among MS patients 
with 40 to 65 percent reporting some form of memory impairment(Chiaravalloti & DeLuca, 
2008). Memory includes the ability to acquire, retain, and retrieve information(Thornton & 
Raz, 1997). MS patients can have a problem with acquisition and effective encoding of 
information, but are often able to retrieve information as effectively as patients without 
MS(DeLuca, Barbieri-Berger, & Johnson, 1994). In addition to working memory difficulties, 
MS patients may display other varied forms of memory impairment. Research has found 
impairment in immediate and delayed recall, episodic, verbal and spatial memory among 
different samples of MS patients(Andrade et al., 1999; Arnett & Strober, 2011; Brissart, 
Morele, Baumann, & Debouverie, 2012). Research has demonstrated that the varied patterns 
of neurological atrophy, particularly in grey matter, partially accounts for differential 
memory impairments seen in MS patients(Benedict et al., 2006; Benedict, Ramasamy, 
Munschauer, Weinstock-Guttman, & Zivadinov, 2009).  
Executive Function  
Nearly 25 percent of MS patients experience problems with organization, planning, 
working memory and abstract reasoning(Chiaravalloti & DeLuca, 2008; Foong et al., 1997; 
Thornton & Raz, 1997). These abilities are commonly known by the broad term, “executive 
functions”. MS patients can demonstrate deficits in verbal fluency, cognitive estimation, 
spatial working memory, spatial span, strategic abilities and the Stroop task(Arnett et al., 
1997; Foong et al., 1997).  Some research has linked executive function disability to 
deterioration of the frontal lobe(Foong et al., 1997) and axonal deterioration(Foong et al., 
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1999), although  the exact location of atrophy in relationship to specific executive function 
deficits has not yet been determined(Foong et al., 1997). 
Beliefs about Multiple Sclerosis  
Patients define and attribute symptoms differently to their disease and frequently have 
diverse beliefs about the cause, severity, and progression of disease (Jopson & Moss-Morris, 
2003). These attributions are known as illness representations and include five core 
dimensions of identity, cause, consequences, timeline, and cure/control(Jopson & Moss-
Morris, 2003). Studies have indicated that how patients process their disease (cognitively and 
emotionally) impacts their coping strategies and reported physical, emotional, and social 
disability. These findings have been replicated among numerous patient 
populations(Chaboyer, Lee, Wallis, Gillespie, & Jones, 2010; Norcini Pala & Steca, 2015; 
Quiles Marcos, Terol Cantero, Romero Escobar, & Pagán Acosta, 2007; Rozema, Völlink, & 
Lechner, 2009; Vollmann, Scharloo, Langguth, Kalkouskaya, & Salewski, 2013; Ziarko, 
Mojs, Piasecki, & Samborski, 2014), including patients with MS when controlling for 
disease severity(Jopson & Moss-Morris, 2003). Patient beliefs about MS may directly impact 
engagement in health behaviors and therefore possess special importance, because some 
behavioral choices (e.g. diet and exercise) may directly or indirectly impact disease 
progression, cognition, emotion, and physical ability by increasing neuroinflammation, 
altering brain insulin, and increasing weight(Parrott & Greenwood, 2007). 
MS patients experience levels of obesity that are at least as high as those in the 
general population(Pilutti, Dlugonski, Pula, & Motl, 2012; Slawta et al., 2003). Research 
estimates that approximately two-thirds of adults in the general population are overweight or 
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obese(Carmona, 2003). There is overlap between symptoms and underlying proinflammatory 
processes that may link worsened disease activity in MS with obesity.  
Obesity  
The prevalence of overweight and obesity in the United States has risen at such an 
alarming rate that obesity is now considered an epidemic(Carmona, 2003). Nearly two-thirds 
of adults in the US were overweight or obese in 2007, based on body mass index (BMI), and 
three-fourths were predicted to meet criteria for overweight or obesity in 2015(Y. Wang & 
Beydoun, 2007). BMI is a ratio of weight to height used to classify weight status. The World 
Health Organization (WHO) defines obesity as a condition of excess body fat to the point 
that health is impaired("Obesity: preventing and managing the global epidemic. Report of a 
WHO consultation," 2000).  
Obesity is a problem of significant global and economic impact. Obese patients cost 
an estimated 30 to 42 percent more per capita in direct medical expenditures per year than 
their healthy weight counterparts(Calle, Rodriguez, Walker-Thurmond, & Thun, 2003; 
Shamseddeen, Getty, Hamdallah, & Ali, 2011). $147 billion was spent on medical 
expenditures associated with obesity in 2008(Finkelstein, Trogdon, Cohen, & Dietz, 2009). 
This accounted for nearly 10 percent of total medical expenditures that year. It has also been 
estimated that indirect economic costs associated with obesity amount to at least 4.3 billion 
dollars annually(Cawley, Rizzo, & Haas, 2007; Shamseddeen et al., 2011). These indirect 
costs are typically associated with physical, emotional, and cognitive disability that translates 
into work absenteeism, loss of productivity, and lost wages. By 2030, it is predicated that 
overweight and obesity will account for 15.8 to 17.6 percent of total health care costs. This 
amounts to annual spending between $860 billion and $956 billion(Y. Wang, Beydoun, 
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Liang, Caballero, & Kumanyika, 2008). The harmful impact of obesity at both an individual 
and global level is related to decrements in physical, emotional, and cognitive function. 
Recent research has revealed the devastating impact that excess weight can have on all forms 
of health(Carmona, 2003).  
Environmental Contributions to Obesity 
When energy intake supersedes energy expenditure for an extended period of time, 
the human body accumulates excess weight. This basic “energy imbalance” accounts for the 
majority of obesity in westernized countries. Importantly, obesity has increased at rates far 
higher than can be accounted for by genetics alone(Wilding, 2012). In rare instances, genetic 
and biological syndromes, such as Prader Willi, Bardet Biedl, and Alstrom, lead to 
obesity(Pérusse et al., 2005). This rarity indicates that social/psychological factors may play 
an important role in the upsurge of obesity rates over the past few decades. Some of these 
environmental factors include increased consumption of processed foods, decreased activity 
levels, endocrine disruptors, use of air conditioning and heat leading to less variability in 
body temperature, and sleep debt. Commonly used medications, such as psychotropic 
medications, diabetic treatments, antihypertensives, steroid hormones and contraceptives, 
antihistamines, and protease inhibitors may also increase the likelihood for obesity(Wright & 
Aronne, 2012). Although the essential basis of the development of obesity is simple, the 
varied social-environmental effects are difficult to tackle effectively at both the individual 
and population level.   
Diagnosis and Treatment of Overweight and Obesity 
BMI is a ratio of weight to height that is used to clinically classify weight status. BMI 
has been strongly associated with negative weight-related health outcomes related to 
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cardiometabolic conditions. BMI values of 25 kg/m
2 
and 30 kg/m
2
 have been designated as 
the respective cutoff points for overweight and obesity. These cutoffs are founded on 
recommendations of the National Heart, Lung, and Blood Institutes and North American 
Association for the Study of Obesity expert committee("Clinical guidelines on the 
identification, evaluation, and treatment of overweight and obesity in adults: executive 
summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in 
Adults," 1998).  
Waist-to-height-ratio (WTHR) has also been indicated as a practical and accurate 
method of overweight and obesity assessment. It uses cutoffs of .40 for low body weight and 
.57 for severe central obesity(Peng et al., 2013). A general cutoff of .50 for women and .53 
for men has been supported as a demarcation between healthy weight and overweight; a ratio 
of .54 in women and .58 in men indicates obesity (Ashwell & Hsieh, 2005). WTHR has been 
shown to be superior to BMI in diagnosing obesity, and identifying risk for cardiovascular 
disease, type II diabetes and metabolic malfunction(Ashwell, Gunn, & Gibson, 2012; 
Ashwell & Hsieh, 2005; Ashwell, Mayhew, Richardson, & Rickayzen, 2014; C. M. Lee, 
Huxley, Wildman, & Woodward, 2008; Rodea-Montero, Evia-Viscarra, & Apolinar-
Jiménez, 2014). It is particularly sensitive to early signs of health risks when compared to 
BMI and other measurements of obesity(Ashwell & Hsieh, 2005).  
Despite the “basic” energy imbalance that leads to obesity, there is no simple, 
effective treatment. Advice to exercise more and eat less typically is unsuccessful in the 
long-term, as few individuals are able to maintain an appropriate balance between diet and 
exercise(van Dale & Saris, 1989). Numerous prescription and over-the-counter treatments for 
obesity have been developed, but most are ineffective in the absence of diet and 
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exercise(Glenny, O'Meara, Melville, Sheldon, & Wilson, 1997; MacLaughlin et al., 2010). 
Thus, many may act as a boost rather than a cure by suppressing appetite or interfering with 
the body’s ability to store fat, calories, and vitamins. Bariatric surgery is touted as the most 
effective form of weight loss(Bougoulia, Triantos, & Koliakos, 2006). Roux-en-Y, 
laparoscopic adjustable gastric banding (LAGB), and gastric sleeve are common procedures 
that reduce stomach volume and induce weight loss via caloric restriction(Buchwald et al., 
2004). Despite success achieved in the first few years following bariatric surgery, many 
patients (up to 40 percent) cannot maintain the weight loss at seven-to-ten years post-
operation(Suter, Calmes, Paroz, & Giusti, 2006). Clinicians continue to highlight the need for 
multi-faceted obesity treatments including support for diet, exercise, hunger reduction 
(medicinal or surgical), and psychotherapy to cope with the issues behind emotional eating. 
Below we outline symptoms of obesity that may overlap with MS. 
Physical Functioning in Obesity 
Decreased physical functioning and impaired mobility are among the most notable 
negative consequences of obesity. Overweight and obese patients are at a higher risk for 
serious and/or life-threatening health problems including: type II diabetes and metabolic 
syndromes, hypertension, heart disease, stroke, certain types of cancer, gout, sleep apnea, 
obesity hypoventilation syndrome, asthma, gallbladder problems, osteoarthritis, stress 
fractures, reproductive problems, and numerous autoimmune diseases(Kopelman, 2007). 
Excess fat obscures the internal organs and prohibits early detection of risk factors for 
conditions like cancer, heart disease, and reproductive problems. It also places surplus strain 
on the bones and muscles of the body which increases the probability that patients will 
experience pain, injury, and fractures. Breathing problems and circulatory problems are 
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common among obese patients(Kopelman, 2007). Added pressure and burden on the lungs 
and circulatory system forces their bodies to work harder when performing autonomic 
functions. Many patients also experience decreased mobility and increased fatigue due to the 
added strain of excess weight and fat(Jadelis, Miller, Ettinger, & Messier, 2001; Messier, 
2008).  
Mobility 
Many obese persons experience problems related to mobility(Messier, 2008). There is 
a strong-positive relationship between obesity and functional impairment, such that as 
obesity and body fat increase, associated functional impairment mirrors this 
increase(Messier, 2008). Patients with high levels of body fat are nearly 200 times more 
likely to experience self-reported mobility-related disability than patients with the lowest 
levels of body fat (Ettinger et al., 1994). One mechanism by which obesity hinders mobility 
is osteoarthritis (OA). OA occurs when protective cartilage at the ends of bones is worn 
down from added weight induced pressure and bones no longer have protective cushioning to 
separate one another. OA of the knee has been specifically linked to mechanical 
complications caused by obesity(Messier et al., 1994). Patients with a BMI of 30kg/m
2
 are 
6.8 times more likely to develop OA of the knee than healthy weight individuals(Messier, 
2008).  
Weakness 
Muscle weakness contributes to decreased balance and increased risk for falls that 
lead to injury and hospitalization(Rubenstein, 2006). Obese individuals show significant 
muscle weakness when compared to their healthy weight counterparts, which may arise from 
reduced physical activity combined with added strain due to excess body mass. Knee strength 
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has been compared in obese and healthy weight mid-to older adults. In healthy weight male 
and female patients, knee strength was 12 percent more of overall individual body weight 
than in obese patients(Miyatake et al., 2000). Other studies have found strong inverse 
relationships between obesity and balance such that increased BMI is associated with 
decreased balance
131
 and this effect is likely more pronounced in women(Kejonen, Kauranen, 
& Vanharanta, 2003).  
Balance 
Obese patients have been shown to change their gait to improve stability and reduce 
pressure on knees and joints(Messier, 2008). Stride length and knee extensor torque is 
reduced in obese patients such that patients with greater BMIs have shorter strides(Messier, 
2008). Higher BMI is also associated with increased use of hamstrings to support the knees. 
This is in contrast to healthy weight patients who primarily use the quadriceps to support 
their knees. In addition, changes in the feet can increase the risk for injury and discomfort. 
Obese patients have been shown to walk with their toes pointed outward up to 276 percent 
more than normal weight patients(Messier et al., 1994). This form of abduction is indicative 
of a greater bodily emphasis on balance which is necessary with less stability(Chodera & 
Levell, 1973). Additionally, obese patients exhibit increased rear foot motion (e.g. more 
pronation range of motion, faster pronation and greater touchdown angle)(Messier, 2008) 
than normal weight individuals. Foot adjustments commonly made by obese patients have 
been linked to a five-fold increased risk of heel pain and/or plantar fasciitis(Riddle, Pulisic, 
Pidcoe, & Johnson, 2003). Overall, greater force is exerted by obese patients which leads to 
increased strain and injury(Kappus et al., 2015; Messier, 2008). 
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Fatigue 
Controversy surrounds the relationship between fatigue and sleepiness in obesity. 
Some researchers have argued that they are fundamentally different, while others have 
argued that they are the same or on the same continuum. In 2005, researchers differentiated 
fatigue from sleepiness by defining fatigue as a tiredness that does not include greater sleep 
propensity(Vgontzas, Bixler, & Chrousos, 2006; Vgontzas, Bixler, Chrousos, & Pejovic, 
2008). Chronic insomnia, elderly sleep disturbance, and psychogenic hypersomnia are 
considered to be conditions associated with fatigue while sleep apnea, narcolepsy, and sleep 
deprivation are conditions associated with increased sleepiness. Obesity research has not 
differentiated between sleepiness and fatigue historically, and it may be difficult to fully 
disentangle the two since patients often experience multiple health complications that are 
associated with fatigue and increased sleep propensity.  
Obese patients experience sleep disorders at rates far higher than seen in the general 
population. In particular, 50 percent of obese patients have obstructive sleep apnea (OSA) 
and obesity increases the risk for OSA by 50 percent (Lurie, 2011; Romero-Corral, Caples, 
Lopez-Jimenez, & Somers, 2010). Patients with OSA may experience symptoms that could 
be interpreted as fatigue, but increased sleep propensity is the differentiating factor(Vgontzas 
et al., 2006).  
Fatigue is believed to originate in obese patients via mechanisms consistent with MS 
fatigue. In some studies, obese patients with fatigue have demonstrated HPA 
hyperactivation(Duclos et al., 2001; Mårin et al., 1992; Pasquali et al., 1993), as seen in MS 
patients. However, researchers propose a more complex model to explain fatigue versus 
sleepiness in obese patients. They suggest that elevation of proinflammatory cytokines (IL-6) 
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in conjunction with HPA hyperactivation and depression leads to fatigue among obese 
patients(Vgontzas et al., 2006). Conversely, they suggest that proinflammatory cytokines (IL-
6) in conjunction with HPA hypoactivation and lack of depression lead to sleepiness. 
Hyperactivation of the HPA axis in conjuction with proinflammatory cytokines is also 
believed to underlie fatigue in MS(Gottschalk et al., 2005; Téllez et al., 2006; Vgontzas et 
al., 2006). Given the similar proposed underpinnings, it is likely that obesity combined with 
MS could produce worse fatigue than experienced by patients who have only one of the two 
conditions. 
Emotional Functioning in Obesity 
Like MS patients, overweight and obese patients experience higher rates of mental 
health problems than those in the general population. Obesity has been associated with an 82 
percent increased odds of having depression and 40 percent increased odds of having 
anxiety(Gariepy, Nitka, & Schmitz, 2010) (Onyike, Crum, Lee, Lyketsos, & Eaton, 2003). 
Depression and anxiety have been consistently shown to impair productivity and 
social/relational and physical functioning within the general population(Judd et al., 2000; 
Klerman, 1989; Klerman & Weissman, 1992). Obesity has also been shown to reduce quality 
of life by inhibiting functional abilities and impairing physical health(Markowitz, Friedman, 
& Arent, 2008). Obese patients with comorbid psychological conditions may experience 
greater overall disability related to social and physical functioning than obese patients 
without depression or anxiety(Markowitz et al., 2008). The exact relationship between 
psychological distress and obesity has not yet been disentangled, but researchers propose a 
bi-directional relationship between the two such that each one may perpetuate and exacerbate 
the other(Markowitz et al., 2008) 
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Obesity as a risk factor/cause for depression  
 Some studies have demonstrated a positive relationship between obesity and 
depression indicating that more severe obesity is associated with increased depression 
incidence(Roberts, Deleger, Strawbridge, & Kaplan, 2003; Roberts, Kaplan, Shema, & 
Strawbridge, 2000). One study found that 15.5 percent of obese patients were depressed in 
comparison with 7.4 percent of normal weight patients(Roberts et al., 2000). Another study 
showed obesity predicted depression one year following assessment (odds ratio= 
1.73)(Roberts et al., 2003). The same study found that obesity also predicted unhappiness, 
pessimism, low positive affect, and life dissatisfaction at five years following the baseline 
interview. Obesity may increase one’s risk for depression and negative affect via physical 
and psychosocial mechanisms.  
Functional impairment, chronic disease, and pain are byproducts of obesity and 
havebeen demonstrated to reduce health-related quality of life (HRQOL)(Kolotkin, Meter, & 
Williams, 2001; Wells et al., 1989). Reduced HRQOL may lead to poorer self-rated health in 
which patients may believe that efforts toward health are futile and subsequently relinquish 
their efforts and succumb to depression(Markowitz et al., 2008). MS patients have also been 
shown to experience higher rates of depression in instances where QOL is reduced(Benito-
León, Morales, & Rivera-Navarro, 2002). 
Stereotypes characterize obese individuals as incompetent, ugly, and lazy(Carr & 
Friedman, 2005). These implicit and explicit judgments are damaging to self-esteem and 
increase social acceptance of cruelty and discrimination in educational, employment, health, 
and social institutions(Carr & Friedman, 2005; Puhl & Brownell, 2003).  Weight-based 
ostracism based may be linked to the high prevalence of body image dissatisfaction among 
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obese/overweight individuals(Friedman & Brownell, 1995). Many report multiple failed diet 
attempts to attain a socially-acceptable body image(Markowitz et al., 2008) These two 
components together may lead to a circular loop of depression and reinforcement of poor 
self-esteem and feelings of failure. 
Depression as a risk factor for obesity  
 Physiological and psychosocial pathways may link depression to obesity. As with 
MS, dysregulated HPA(De Bellis, Gold, Geracioti, Listwak, & Kling, 1993), sustained 
elevations in cortisol(Lupien et al., 1998; Lupien et al., 1999), and increased 
proinflammatory cytokines (TNF, IL-1, IL-6, interferon-γ)(Kenis & Maes, 2002; Kubera, 
Maes, Kenis, Kim, & Lasoń, 2005)  may be pathogenic to depression in obesity(Kern et al., 
2011). Dysregulation of these systems has been shown to promote weight gain and may 
explain the physiological mechanisms that link depression to obesity(Greeno & Wing, 1994). 
Some evidence indicates that depression is linked to future obesity via dysregulated eating, 
reduced self-efficacy, and poor social support. Depressed individuals may not possess 
adequate life coping strategies and some turn to large  quantities of food (i.e. binge) to 
regulate mood in the context of emotional upset(Markowitz et al., 2008). Self-efficacy to 
control weight and eating may quickly disintegrate when patients experience overwhelming 
feelings and the sense that they’ve “lost control.” A lack of social support may only 
exacerbate feelings of failure and reduced self-efficacy to cope with life and manage 
weight(Bishop, 2002). The exact directionality between obesity and depression is not fully 
understood. Models that exist suggest that each confers risk for the other and may create a 
cycle in which depression and obesity are maintained.  Moreover, these mechanisms may 
interact with the biosocial factors that link MS with an increased incidence of depression. 
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Obesity may expose MS patients to further physiological disruption and social stigma that 
result in the development of depression. 
Cognitive Functioning in Obesity 
Excess weight contributes to an increased risk for stroke and decreased risk of full 
recovery following a stroke or brain trauma(Weitbrecht & Kirchhoff, 1995). However, risks 
for cognitive decline among the obese are not just related to stroke; recent research indicates 
that structural, hormonal, and biochemical changes may lead to poorer cognitive performance 
among the obese.  
Diffuse atrophy(Benedict et al., 2006; Benedict et al., 2009) in MS has been 
associated with worse cognitive performance and the effects of brain atrophy on cognitive 
function are also seen among the obese. Enlarged orbitofrontal white matter, reductions in 
focal gray matter volume in the frontal lobes, and axonal/myelin abnormalities of the frontal 
lobes have been observed in overweight and/or obese young adults(Pannacciulli et al., 2006). 
The frontal lobes are particularly susceptible to age-related declines in functioning(Bruce-
Keller, Keller, & Morrison, 2009). Morphological changes of the frontal lobes among 
overweight/obese patients are likely due to neuron loss and may indicate premature aging.  
Deficits in processing speed(Yim et al., 2012), memory, learning, and executive functioning 
have been demonstrated by obese/overweight individuals in comparison to healthy weight 
indivduals(Elias, Elias, Sullivan, Wolf, & D'Agostino, 2003, 2005; Gunstad et al., 2007; 
Waldstein & Katzel, 2006), and these functions have been well-associated with functioning 
in the frontal lobes (Dodds, Morein-Zamir, & Robbins, 2011; du Boisgueheneuc et al., 2006; 
Hampshire, Chamberlain, Monti, Duncan, & Owen, 2010). Morphological changes resultant 
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from obesity may underscore the link between obesity and poor cognitive performance 
relative to healthy weight individuals.  
 Poorer cognitive function in obese patients may also be due to metabolic 
syndrome(Farr et al., 2008), high cholesterol, and chronic hyperglycemia(Kanaya, Barrett-
Connor, Gildengorin, & Yaffe, 2004; Morley, 2004). Strong evidence exists for the role of 
triglycerides in cognitive deterioration. Triglycerides ultimately break down into free fatty 
acids which can bind to specialized receptors in the brain (ex. GPR40)(Ma et al., 2008). This  
signals a cascade of inflammation and astrocytic and microglial activity which can disrupt 
cognition by reducing long-term potentiation in the hippocampus and impairing leptin 
transport at the blood brain barrier which subsequently triggers leptin resistance(Banks et al., 
2004; Farr et al., 2008; Patil & Chan, 2005).  Leptin is widely distributed throughout the 
brain and is involved in the regulation of neuronal excitability, control of appetite and 
energy(Elmquist, Bjørbaek, Ahima, Flier, & Saper, 1998; Fei et al., 1997; Harvey, 2007). 
Dysregulated leptin can influence microglial inflammatory cascades that lead to oxidative 
stress and inflammation of the brain linked to cognitive decline(Bruce-Keller et al., 2009). 
Rodent studies have shown that signals of oxidative stress in the brain are reduced when 
triglyceride levels are lowered with medication thus highlighting the link between higher 
levels of triglycerides and inflammatory processes in the central nervous system. 
Excess endogenous corticosterone and other glucocorticoids are found in obese and 
diabetic patients(Dallman et al., 2006). These glucocorticoids bind to receptors that regulate 
sugar metabolism and thereby decrease immune function and increase sugar production and 
levels in the blood. Increased blood sugar is associated with advanced glycation end products 
that can impair neurogenesis in the hippocampus, synaptic plasticity and cognitive 
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function(Stranahan, Arumugam, et al., 2008; Stranahan, Lee, et al., 2008). Indeed, the 
cognitive detriment associated with obesity may be due to complex interplay between 
physiologic, immunologic, and homeostatic mechanisms and these may negatively interact 
with MS and create further decline in functioning.  
Beliefs about obesity  
Overweight and obese patients have been shown to underestimate their weight status 
as determined by BMI(Irani & Abell, 2007; Johnson-Taylor, Fisher, Hubbard, Starke-Reed, 
& Eggers, 2008). Men have historically been more likely than women to underestimate their 
overweight or obesity status(Paeratakul, White, Williamson, Ryan, & Bray, 2002). However, 
as rates of obesity continue to climb, women have decreased in accurate categorization of 
themselves as healthy weight, overweight, or obese(Gillum & Sempos, 2005). Parents also 
demonstrate poor awareness of overweight/obesity in their children; nearly 90 percent of 
parents with overweight children underestimate their child’s weight status significantly 
(Baughcum, Chamberlin, Deeks, Powers, & Whitaker, 2000; Carnell, Edwards, Croker, 
Boniface, & Wardle, 2005; Etelson, Brand, Patrick, & Shirali, 2003). Poor awareness of 
weight status is further compounded by poor understanding of health risks associated with 
obesity. Nearly a quarter of individuals in the US believe that one can be “significantly 
overweight” and still healthy(T. Thompson et al., 2013). Furthermore, the majority of 
individuals do not recognize a connection between obesity and health complications beyond 
heart disease and diabetes(T. Thompson et al., 2013). Fewer than one in five individuals in 
the US recognize a connection between obesity and high blood pressure, arthritis/joint 
problems, high cholesterol, mental health issues, stroke, cancer, and death. Reduced 
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awareness of overweight/obesity status may partially underlie failure to take precaution 
against health risks associated with obesity(Fleary & Ettiene, 2014).  
Beyond basic miscalculation of weight status and complications associated with 
excess weight, patients may also differ in underlying beliefs about the etiology of obesity. 
Research has demonstrated that patients who believe their weight is out of their control (i.e. 
inherited)  are more apt to report themselves as overweight, and report reduced health than 
patients who believe that weight is within their control (i.e. behavioral and due to poor 
diet/lack of exercise)(Fleary & Ettiene, 2014). Patients who believe weight is out of their 
control report higher weight and worse health; however, they also report less exercise and 
lower consumption of fruits and vegetables(C. Wang & Coups, 2010). This may indicate an 
attribution style that promotes acceptance of one’s weight, but hinders taking action that may 
affect or improve weight. No research has been conducted examining MS patients’ 
perceptions of obesity, which is one aim of the present study. 
Physiological Relationship between Obesity and MS 
The prevalence of obesity in the general population is of epidemic proportions. If 
obesity exacerbates or contributes to the development of MS it must be addressed in research 
and practice. Recent evidence indicates that there may be a link between leptin and the 
pathogenesis and/or exacerbation of MS(Matarese et al., 2008).  
Leptin is necessary for healthy development of neural and glial cells, but can trigger a 
cascade of negative effects when at improper levels(Matarese et al., 2010; Matarese et al., 
2008). It is a hormone that is derived from adipocytes in proportion to the amount of adipose 
tissue. Serum leptin levels are positively associated with BMI, weight, and body fat 
percentage among obese patients(Al Maskari & Alnaqdy, 2006). Thus, patients with higher 
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weight and body fat also have higher levels of leptin. When leptin is present in high levels, 
such as with leptin resistance seen in obesity, IFN -y and IgG2a are produced and Treg cell 
production is down-regulated producing significant inflammatory cascades. 
Rates of obesity and overweight in the MS population are nearly equivalent or higher 
than in the general population(Matarese et al., 2010; Matarese et al., 2008). One-quarter of 
MS patients were obese and one-third were overweight in 2008 and those numbers are 
estimated to be higher today(R. Marrie et al., 2009). Moreover, RRMS patients exhibit higher 
levels of leptin and lower levels of Treg cells than matched individuals without MS(Matarese 
et al., 2010; Matarese et al., 2008). Considering that both obese and MS patients individually 
have higher leptin levels, it can be reasoned that those with both MS and obesity are likely at 
a higher risk for inflammatory cascades signaled by excess leptin. Indeed, leptin and/or 
obesity may be an important pathogenic link to MS(Matarese et al., 2010; Matarese et al., 
2008). This is further underscored by research indicating that obesity during adolescence, 
prior to age 20, results in a two-fold increased risk for developing MS(Langer-Gould et al., 
2013; Munger et al., 2013; Munger et al., 2009). Research has indicated that this effect may 
be especially pronounced in females. Because women have higher leptin levels than men, it 
may partially account for the increased prevalence of MS among women(Matarese et al., 
2008).  
Conversely, deficient leptin levels have been linked to impaired immune function and 
increased risk for infection. However, leptin deficiency also acts as a protective mechanism 
against the mouse model of MS (experimental autoimmune encephalomyelitis 
(EAE)(Matarese et al., 2008). This may be due in part to the inverse relationship between 
leptin and Treg cells. Increased Treg cell count is associated with improved disease course in 
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EAE mice. These concurrent effects increase/allow inflammation related to exacerbation of 
MS. Research linking leptin to MS is relatively new and is not a fully inclusive explanation 
of pathogenesis. However, the existing research suggests that obesity may compound 
physical, emotional, and cognitive difficulties in MS patients via leptin-initiated 
inflammatory cascades.    
Research of Weight Related MS Function 
There is a relative dearth of research linking obesity and increased MS severity. A 
few studies have examined factors associated with obesity among MS patients. Research has 
shown that obesity and related comorbidities (e.g. hypertension, hyperlipidemia, and heart 
disease) are related to increased lesion burden and brain atrophy(Kappus et al., 2015). It is 
possible that neural inflammation and destruction are responsible in part for increased 
symptoms experienced by overweight/obese patients. In particular, MS patients with higher 
risk for cardiovascular disease had more lesions and increased brain atrophy(Kappus et al., 
2015; Weiland et al., 2015). The added physical burden from excess weight may be 
responsible for worse outcomes by impairing physical function and enhancing negative 
psychosocial experiences.   
Physical function in overweight/obese MS patients 
Obesity may play a role in the deterioration of physical function above and beyond 
that caused by MS. Two studies have examined differences in mobility among healthy 
weight and overweight/obese MS patients(R. A. Marrie et al., 2010; Pilutti et al., 2012). The 
first study examined mobility outcomes in patients enrolled in the North American Research 
Committee on Multiple Sclerosis Registry (NARCOMS). They found that patients who 
reported one risk factor associated with cardiovascular disease (e.g. hypertension, 
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hypercholesterolemia) experienced a 51 percent increased risk of early ambulatory disability 
and those with two or more risk factors for cardiovascular disease experienced more than 200 
percent increased risk for early ambulatory disability(R. A. Marrie et al., 2010). However, 
another study examined extensive mobility outcomes among 168 individuals with varying 
MS subtypes (approximately 80 percent RRMS). They found no association between BMI 
group (healthy weight, overweight, obese) on measures of mobility including the timed 25 
foot walk, 6 minute walk, oxygen cost of walking, spatiotemporal gait parameters, and self-
reported walking impairment (Pilutti et al., 2012). This study included well-validated and 
reliable mobility measures, but the relatively small sample of SPMS and PPMS within this 
study may have obscured the effect of obesity on mobility function. Examination of the 
effect of obesity on mobility among other subtypes of MS could indicate that the effects of 
obesity on mobility are delayed and only become apparent as disease course worsens. 
Other studies have examined the relationship between obesity and disability in MS. In 
one, self-reported obesity at baseline was associated with higher disability as measured by 
Patient Determined Disease Steps (PDDS) at 12 months but not at 24 months. Another study 
grouped patients into categories of mild, moderate, and severe disability based on self-
reported PDDS and did not find significant differences in self-reported BMI among groups 
(R. Marrie et al., 2009). However, studies that assessed BMI and disability (EDSS) 
objectively found that BMI was associated with higher levels of disability, but not for risk of 
relapse(Tettey et al., 2014) .Obesity has also been examined as a correlate of fatigue in MS. 
Higher BMI and poorer self-reported dietary habits were associated with increased physical 
fatigue measured with the Fatigue Severity Scale (FSS)(Weiland et al., 2015). However, 
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another study found no association between BMI and general, physical, or mental fatigue 
after adjusting for age(Trojan et al., 2007). 
The above studies paint a complicated picture of the impact of weight on physical 
function. In the present study, we sought to improve upon the methodology of prior studies 
by objectively measuring BMI and adding an additional measure of waist-to-height ratio. 
Well-validated measures of mobility were used and an additional measure of balance was 
included. Common measures of mobility only measure speed, but balance data provides 
information regarding an individual’s general stability and core strength: two factors that are 
needed to perform everyday activities efficiently and without injury. Fatigue was assessed 
with a multi-dimensional measure of fatigue that has been specifically validated with MS 
patients.  
Emotional function in overweight/obese MS patients 
Increased incidence of depression in overweight/obese individuals has been well-
documented and this relationship extends to the MS population(Cambil-Martín et al., 2014; 
Taylor et al., 2014). In one study, MS patients who met criteria for obesity had significantly 
increased odds of experiencing depression (OR= 2.18; adjusted OR= 1.47) and those with the 
least healthy diets (i.e. lowest quartile), on the dietary habits questionnaire, also experienced 
increased risk of depression (OR=4.86; adjusted OR= 2.73)(Taylor et al., 2014). The 
relationship between poor diet and depression was described by the authors as “dose-
dependent” such that as diet worsens, the incidence of depression increases. In another study, 
overweight patients reported higher levels of depression than healthy weight 
patients(Cambil-Martín et al., 2014). Research has primarily focused on the relationship 
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between obesity and depression; therefore, this study will examine the relationship between 
both depression and anxiety and obesity.  
Cognitive function in overweight/obese MS patients 
Despite the known effects of obesity on cognition, no known studies examining 
cognitive function in healthy weight and overweight/obese MS patients were found for this 
literature review. The current study will fill in this gap by assessing the relationship between 
weight status and memory, processing speed, and executive function (verbal fluency).  
MS patient beliefs about weight and disease progression 
 MS patients exhibit levels of obesity as high as or higher than that found in the 
general population(Slawta et al., 2003). It is important to determine what MS patients know 
and believe about the impact of weight on MS symptoms and progression given that a strong 
association may exist(Matarese et al., 2010; Matarese et al., 2008). No known studies have 
examined how MS patients believe their functional abilities are affected by current weight 
and/or future weight gain or weight loss. MS patients who do not see a connection between 
MS symptom expression and weight may be less likely to engage in health behaviors related 
to weight maintenance and may be more likely to be overweight or obese. It is possible that 
overweight/obese patients discount the effect of excess weight on symptoms and progression 
and therefore express less motivation to change obesogenic behaviors. Patients who do not 
see a connection between weight status and worsened MS symptoms may need greater 
benefits for smaller behavior change and may also require additional resources. By 
understanding patient knowledge and beliefs about weight, MS, and their interaction with 
one another, it may be possible to help clinicians develop targeted interventions to strengthen 
motivation and commitment to maintain healthy weight behaviors among MS patients. 
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Summary and Significance 
A link between leptin and the development/exacerbation of MS has been 
proposed(Matarese et al., 2008). Higher levels of leptin induce inflammation that feeds into 
the cycle of neuronal destruction in MS. Both MS and obese patients exhibit higher levels of 
leptin than their healthy weight or non-diseased counterparts. The close overlap in the 
inflammatory and symptomatic profiles of obesity and MS highlights the possibility that they 
may be related(Matarese et al., 2010; Matarese et al., 2008). The research that has examined 
differences in cognition, physical ability and emotional health among healthy weight and 
overweight/obese MS patients has shown inconsistent results and can be methodologically 
improved. Additionally, it is currently unknown how healthy weight and overweight/obese 
patients think about the impact of weight on their disease symptoms and progression. Patients 
who do not believe weight negatively impacts their MS may be unmotivated to engage in 
health behaviors that could possibly improve MS symptoms and quality of life. Such patients 
may place more value on the costs of weight maintenance behaviors, like exercise, and 
therefore require greater rewards to participate in exercise. Gaining an understanding of how 
patients think obesity interacts with MS and how patients analyze costs and benefits of health 
behaviors may enable clinicians to develop targeted interventions to help MS patients gain 
motivation to lose excess weight and maintain healthy dietary and exercise habits. Thus, it 
may be possible to reduce symptoms in MS patients by supporting healthy weight loss and 
weight maintenance interventions. 
Specific Aims and Hypotheses 
The aims of this study were to investigate the association between obesity and MS 
symptoms and disability.   
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1) Examine the relationship between obesity and cognitive/physical/emotional 
functioning among healthy weight and overweight/obese MS patients. It was 
hypothesized that excess body weight would be associated with poorer 
cognitive performance on measures of processing speed, memory, and 
executive function than healthy weight patients. It was also hypothesized that 
excess body weight would be associated with worse physical functioning on 
measures of disability, mobility, balance and physical fatigue. Finally, excess 
body weight was hypothesized to be associated with greater depression, and 
anxiety.  
2) Examine MS patient beliefs about the impact of excess weight on MS 
symptoms and disease progression, and determine reasons for and barriers to 
implementation of health behaviors among healthy weight and 
overweight/obese MS patients. It was hypothesized that excess body weight 
would be associated with reduced belief in one’s ability to affect their weight 
and illness and reduced belief that weight has an impact on MS symptoms. 
Excess body weight was also expected to be associated with increased barriers 
to exercise and eating a healthy diet.  
3) Explore MS patient beliefs about the impact of weight gain or loss on MS 
related symptom severity and fatigue severity. It was hypothesized that MS 
patients would perceive an association between body weight and symptom 
severity and that patients would predict the worst symptom severity for the 
most obese silhouettes.  
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4) Explore MS patient willingness to engage in exercise for hypothetical 
symptom improvement on the EWT. It was hypothesized that patients would 
report increased willingness to exercise for longer periods of time in exchange 
for higher percentages of symptom improvement.  
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CHAPTER 2 
METHODOLOGY 
Participants 
Eighty-one patients with Multiple Sclerosis (MS) with either Relapsing Remitting 
(RRMS) or Secondary Progressive (SPMS) were recruited from a large specialty clinic in the 
Kansas City metropolitan area and by advertisements sent out to the community in the MS 
Society Newsletter.  Eligible patients were required to have a confirmed diagnosis of MS 
and: (a) no movement impairments that would inhibit them from walking up to 25 feet; (b) 
no sensory impairments that might interfere significantly with cognitive testing; (c) no 
developmental history of learning disability or attention-deficit/hyperactivity disorder; (d) no 
neurologic  condition other than MS that could substantially affect cognition (ex. no history 
of stroke or brain surgery); (e) no relapse and/or corticosteroid use within four weeks of 
assessment; (f) no history of alcohol or substance abuse disorder; (g) absence of severe 
physical/neurological impairment that would make testing insurmountable; (h) not have a 
BMI significantly below weight (i.e. below 17).  
Procedure 
Research personnel advertised via an MS newsletter and approached potential 
participants at an MS specialty clinic. Personnel described the study to potential participants 
who expressed interest and screened them at that time to determine eligibility. Following 
eligibility screening, the researcher set up a time to meet with the participant for a two hour 
testing session. When participants arrived for the session, the study was explained and 
participants were given time to review and sign the informed consent document. A study ID 
number was assigned to each participant so that names and other identifying information 
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would not be connected with study obtained data. A master key that contains participant 
identifying information attached with study ID number was maintained throughout the 
duration of the study in the event that a participant asked for their data to be removed. This 
key was stored separately from de-identified data in a separate, locked filing cabinet and was 
only be accessible to the principal investigator and study coordinator. At the conclusion of 
the study, this key was destroyed.  
The two hour testing sessions were conducted in a quiet and private testing room. 
During the testing session, participants filled out demographic information and self-report 
questionnaires. They completed physical and neuropsychological cognitive testing. 
Participants’ height, weight, and waist circumference were recorded following testing. 
Payment of $40 was mailed to participants within a month of study completion.  
Materials and Measures 
Demographic 
 Demographic information was obtained at the beginning of the study from 
participants. This included age, date of birth, sex, ethnicity, education attained, household 
income, and number of individuals in their home. Patients also completed forms that assessed 
disease duration, disability, severity, and medication use.  
Anthropometric  
Body Mass Index 
Participants were instructed to take off their shoes for weight and height to be 
recorded. A Befour MX805 Measurement Station and Column Scale was used for height and 
weight measurement. BMI was then calculated with the Center for Disease Control’s 
calculator.  It is calculated as (weight in pounds X 703)/ height in inches
2
.  
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Waist Circumference 
 Researchers measured waist circumference at the thinnest portion of the waist 
between the iliac crest and the bottom portion of the ribs with a tape measure. Participants 
were asked to breathe out during the measurement to ensure reliability of measurement 
procedures.  This process was repeated three times and the average circumference was 
calculated for each patient and then divided by height in inches to calculate waist to height 
ratio(Ashwell et al., 2012; Ashwell & Hsieh, 2005; Ashwell et al., 2014; Bosnar-Puretić, 
Basić-Kes, Jurasić, Zavoreo, & Demarin, 2009; Hara, Saitou, Iwata, Okada, & Harada, 2002; 
C. M. Lee et al., 2008; Rodea-Montero et al., 2014). Research assistants were trained to 
measure waist circumference by the study coordinator and tested to ensure accuracy. 
Physical  
Mobility  
The 25-Foot Walk is a functional test of mobility designed to assess gait speed. It 
includes two trials during which patients are instructed to walk as quickly as possible for 25 
feet. The two trials are averaged for a final score. It has been validated for use with many 
patient populations including MS patients as a part of the Multiple Sclerosis Functional 
Composite (Bethoux & Bennett, 2011; Fischer, Rudick, Cutter, & Reingold, 1999). This 
procedure was completed by participants during the testing session. 
Balance  
The SWAY Balance Mobile Application (SWAY Medical, Tulsa, OK, USA) is an 
application that can be installed on an apple touch screen device. Users perform a series of 
five stance conditions for 10 seconds each with open eyes. It uses output from triaxial 
accelerometers during the stances to generate a stability score for movement in the anterior/ 
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posterior and medial/lateral plane. Preliminary research has indicated that the SWAY balance 
software exhibits concurrent validity with validated balance measures including the Biodex 
Balance System SD and BESS(Jeremy A. Patterson, Amick, Pandya, Hakansson, & 
Jorgensen, 2014; J. A. Patterson, Amick, Thummar, & Rogers, 2014). This procedure was 
completed by participants during the testing session. 
Fatigue 
 The Modified Fatigue Impact Scale (MFIS)(Fisk et al., 1994; Ritvo, 1997)  is a 21-
item inventory that has demonstrated good internal reliability in patients with MS 
(cronbach’s alpha= .81-.85). Patients completed the full version MFIS as well as a shorter 
five-item version (MFIS-5) during a different activity. The 21-item version can be used to 
calculate subscale scores for physical, cognitive, and psychosocial fatigue(Fisk et al., 1994). 
The MFIS-5 has demonstrated good reliability (cronbach’s alpha= .80)(Ritvo, 1997). 
Participants rate five-items on a five-point scale that assess the impact of fatigue during the 
past 4 weeks. 
Stroke Risk Factors 
 The Stroke Risk Scorecard is an eight item self-report questionnaire that assesses 
factors associated with risk for stroke including blood pressure, atrial fibrillation, smoking, 
diabetes, physical activity, weight and family history of stroke. The Stroke Risk Scorecard 
was developed by the National Stroke Association to be used as a self-screener and scored 
using the total of the items(Association, 2015). The Stroke Risk Scorecard includes items 
that have been reliably shown to be related to risk for stroke and heart attack(Go et al., 2014; 
Mozaffarian et al., 2015).  We chose to include the Stroke Risk Scorecard in our analyses 
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because the items it assesses are associated with poor health behaviors and 
obesity(Kopelman, 2007).  
Emotion 
Depression and Anxiety 
 The Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) The HADS is 
a self-report scale that assesses depression and anxiety with a total of 14 items. Patients are 
asked to answer statements (e.g. “I feel restless and have to be on the move”) on a scale that 
ranges from zero to three. It has demonstrated good validity and high internal consistency 
and test-retest reliability(Bjelland, Dahl, Haug, & Neckelmann, 2002).  
Cognition 
Processing Speed  
 The Symbol Digit Modalities Test (SDMT)(Benedict et al., 2012; Smith, 1982) 
assesses speed of information processing, visuoperceptual processing, and attention by 
requiring participants to say numbers that corresponds with symbols according to a key. 
Correct responses within a 90 second time period are measured for the variable of interest. 
Research has shown that the SDMT has strong test-retest reliability (r > .80)(Benedict et al., 
2012). The SDMT is commonly used to assess cognitive dysfunction in MS patients 
(Parmenter, Weinstock-Guttman, Garg, Munschauer, & Benedict, 2007).  
Verbal Memory  
 The Rey Auditory Verbal Learning Test (AVLT)(Lezak, 1995) assesses verbal memory 
during five learning trials and one delayed recall trial. During this task, participants learn and 
are subsequently asked to recall a list of words. The dependent variables of interest are 
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correct responses during the delay recall trial. Validity for the Rey AVLT has been found for 
patients with MS(Geffen, Butterworth, & Geffen, 1994; Ryan & Geisser, 1986).  
Executive Function   
 The Controlled Oral Word Association Test (COWAT)(Ruff, Light, Parker, & Levin, 
1996) has been designed to assess verbal fluency by requiring patients to spontaneously 
produce words orally that begin with a specific letter of the alphabet. The test includes three 
trials and patients are forbidden from saying proper nouns (e.g. names and numbers) and the 
same word with a different ending (e.g “eat” and “eating”). Patients are given 60 seconds for 
each of three trials.  Research has shown that the COWAT is sensitive to brain dysfunction 
and displays high reliability (cronbach’s alpha= .83) and test-retest reliability (r = .74)(Ruff 
et al., 1996) as well as validity with MS patients(Gromisch et al., 2016).  
Beliefs about weight, MS, and their interaction  
Barriers to Weight Maintenance  
 A 25 item survey was modified for use in this study. The original survey has been 
validated among women and shown to express good internal reliability (Cronbach’s alpha 
.68-.83)(Andajani-Sutjahjo, Ball, Warren, Inglis, & Crawford, 2004). Barriers used in this 
survey have been well-documented in other studies assessing barriers to physical activity and 
healthy eating(Andajani-Sutjahjo et al., 2004).  
MS Specific Health Beliefs  
 For the purpose of this study, we developed 8 questions specifically pertaining to 
beliefs about the impact of weight on MS symptoms and progression. Analyses following the 
study revealed that this questionnaire exhibits high reliability (Cronbach’s alpha= .94). 
Participants rated 8 items on a 6 point Likert scale with response options ranging from 
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strongly agree to strongly disagree. Items developed for this study include: 1. I believe that 
eating a healthy diet will improve my MS; 2. I believe that exercising consistently will 
improve my MS; 3. I believe that eating healthy may slow the progression of my MS; 4. I 
believe that exercising may slow the progression of my MS; 5. I experience fewer symptoms 
(or my symptoms improve) when I eat healthy; 6. I experience fewer symptoms (or my 
symptoms improve) when I exercise on a consistent basis; 7. I believe that maintaining a 
healthy weight will slow the progression of my MS; 8. I believe that maintaining a healthy 
weight may improve my MS symptoms.  
Dieting Beliefs  
 The Dieting Beliefs Scale(Stotland & Zuroff, 1990) is a 16-item measure that assesses 
individual’s beliefs that they can affect or control weight (i.e. weight locus of control 
(WLOC)) and includes one internal and two external factors related to internal and external 
locus of control. Items are scored on a likert type scale with options ranging from 1 (i.e. “not 
at all descriptive of my beliefs”) to 6 (i.e. “very descriptive of my beliefs.”) It has 
demonstrated acceptable internal consistency (Cronbach’s alpha= .69) and test-retest 
reliability (.81).  Higher scores indicate a paradigm consistent with an internal locus of 
control.  
Beliefs about the impact of weight change on symptom severity and fatigue 
Body Size and Symptoms Task (BSS)  
 We used the Figure Rating Scales to create a novel paradigm called the Body Size 
and Symptoms (BSS) task (See Appendices A and B) (A. Stunkard, 2000; A. J. Stunkard, 
Sørensen, & Schulsinger, 1983). The Figure Rating Scales consist of nine female and nine 
male silhouettes of increasing body mass. They have demonstrated good reliability and 
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validity and BMI norms for each figural stimuli have been determined (Bulik et al., 2001; A. 
Stunkard, 2000). The BSS uses the Figure Rating Scales to assess patient predicted symptom 
severity at silhouettes of varying increasing and decreasing weight. Participants were asked 
to estimate symptom severity on a scale from “0” to “6” for several symptoms (e.g. physical 
and cognitive fatigue, pain, balance, walking speed, sleep quality, memory, processing speed, 
sexual function, depression, anxiety, severity of exacerbations and number of yearly 
exacerbations) at silhouettes of varying weight status (e.g. underweight (silhouette 1), healthy 
weight (silhouette 4), and obese (silhouette 9). Patients also completed this activity for the 
Modified Fatigue Impact Scale (MFIS).  
Willingness to Exercise for Symptom Improvement  
Exercise Willingness Task (EWT) (See Appendix 3).  
 This novel task was designed to assess the extent to which patients are willing to 
endure inconvenience (i.e. time spent exercising) to hypothetically improve MS symptoms 
immediately and at a delayed time point of five years. Patients were asked to rate the amount 
of time they would be willing to allocate to exercise to receive varying percentages of 
symptom improvement for different symptoms (e.g. if you knew your cognitive fatigue 
would improve by 50% immediately, how many minutes of exercise would you be willing to 
do per day?). See Appendix II for items used in this study. 
Statistical Analyses 
 Data were entered into IBM Statistical Package for the Social Sciences version 
24.0and reliability was checked by other research team members to ensure accuracy. Group 
differences in demographic data (age, education, gender, disease, subtype, disease duration) 
were examined with correlations, T- tests, and Chi-Square tests.  
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The first aim of this study was to examine the impact of excess body weight (per BMI 
guidelines and WTHR guidelines) on measures of cognition, physical function, and 
emotional distress. To reduce familywise error, Z-score composite variables were created for 
cognitive and physical measures. Partial correlations were used to examine the associations 
between WTHR, BMI and composite measures of cognitive and physical function as well as 
measures of emotional function and stroke risk while controlling for the impact of age. 
Follow-up Partial correlations were used to examine significant associations with specific 
measures from which composite variables were created.    
The second aim was to examine patient beliefs about the impact of weight on MS 
symptoms and progression. Partial correlations were used to examine associations between 
BMI, and WTHR on measures of dieting beliefs, MS specific health beliefs and barriers to 
diet and exercise while controlling for the effect of age.  
The third aim was to explore patient beliefs about the impact of excess body weight 
on symptom severity using the Body Size and Symptoms (BSS) task. Mixed-factor Analysis 
of Variance (ANOVA) statistics were used to examine within subject symptom severity 
rating at silhouettes 1, 4, and 9 for both general symptoms (ex. cognitive fatigue, physical 
fatigue) and MFIS with current symptom severity (higher or lower symptoms) as the between 
subjects variable. In the event that homogeneity of variance was violated, nonparametric 
statistics were used to evaluate within subject and between group differences. 
The fourth aim was to explore MS patients’ willingness to exercise to achieve 
increasing percentages of symptom improvement using the Exercise Willingness Task 
(EWT).  Mixed-factor ANOVAs were used to examine within subject willingness to exercise 
to achieve improvement at increasing percentages of improvement. Current symptom 
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severity (lower vs. higher symptoms) was used as the between subjects factor. In the event 
that homogeneity of variance was violated, nonparametric statistics were used to evaluate 
within subject and between group differences.  
Power Analysis An a priori power analysis was conducted with G*Power to determine 
necessary sample size. It indicated that with the significance criterion set at α = .05 for small-
medium effects (.15) and power of β = .8, a sample size of 78 is sufficient.  
Previous studies have found effect sizes ranging from small to large when examining 
the impact of weight on mobility in MS(Pilutti et al., 2012). Other studies have found similar 
and larger effect sizes when  comparing obese and healthy weight individuals on measures of 
cognition (effect size = .13- .55)(Kuo et al., 2006; Vancampfort et al., 2014), 
fatigue(Resnick, Carter, Aloia, & Phillips, 2006), and depression (effect size= .237)(Yim et 
al., 2012) indicating that this study is reasonably powered. 
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CHAPTER 3 
RESULTS 
Descriptive Statistics 
The sample included 81 patients with MS, 64 of whom were female (79.0 %). In this 
sample, the average BMI was 28.69 +/- 7.13 kg/m
2
 and the average waist to height ratio was 
.54 +/- .10inches.  Table 1 displays demographic characteristics of the sample. 
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Table 1 
Descriptive characteristics of the sample 
 MS Patients 
 n (%) or Mean (SD) 
Gender  
       Female 64 (79%) 
       Male 17 (21%) 
Race  
       Caucasian 67 (82.7%) 
       African American 7 (8.6%) 
       Hispanic/Latino 6 (7.4%) 
       Asian/Pacific Islander 1 (1.2%) 
Age (years) 48.01 (11.68) 
Education (years) 14.68 (2.74) 
MS subtype  
       Relapsing Remitting 76 (93.8%) 
       Secondary Progressive 5 (6.2%) 
Duration of Diagnosis (years) 12.25 (9.03) 
PDDS 1.98 (1.79) 
WTHR .54 (.10) 
BMI 28.69 (7.13) 
Note. PDDS = Patient Determined Disease Steps; WTHR = Waist to Height Ratio; BMI = 
Body Mass Index 
Impact of Overweight and Obesity  
 Table 2 shows Spearman correlations between WTHR, BMI and demographic 
variables.  WTHR was significantly associated with age, but not education, disease diagnosis 
duration, gender, ethnicity or subtype.  As a result, age was entered as a covariate into the 
analyses where WTHR was used as a continuous variable. T-tests and Chi-Square tests were 
used to examine differences between healthy weight and overweight/obese groups on 
demographic variables. Categorical WTHR was not associated with any demographic 
variables. Therefore, no demographic covariates were included in mixed-factor ANOVAs.   
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Table 2 
Spearman correlations between WTHR, BMI and demographic variables  
 
 Age Education Disease 
Duration 
Subtype Gender Race 
WTHR .240
**
 -0.111 0.082 0.037 0.046 -0.125 
BMI 0.075 -0.048 -0.030 -0.083 0.044 -0.120 
 
Note: 
** Correlation is significant at the 0.01 level (2-tailed). 
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Table 3 
Descriptive statistics for healthy weight and overweight/obese MS Patients based on 
categorical WTHR  
 
 
 
Variable 
MS Healthy Weight 
n=41 
M         SD 
MS Overweight/Obese 
n=40 
M        SD 
 
 
 
t (df) 
 
 
 
P 
Age (years) 46.24 12.06 49.83 11.13 -1.39 (79) .169 
Education 
(years) 
14.90 3.35 14.45 1.96 .745 
(64.88)
 a
 
.459 
Diagnosis 
duration (years) 
12.17 10.33 12.33 7.60 -.076 (79) .939 
Body Mass 
Index (BMI) 
23.84 3.41 33.66 6.50 -8.49 
(58.63)
a 
.000 
Waist-to-height 
ratio (WTHR) 
.458 .040 .621 .073 -12.43 
(59.93)
a 
.000 
      
 
X
2
(df) 
 
 
P 
Subtype RRMS (N= 
38) 
 SPMS (N= 
3) 
 RRMS 
(N= 38)  
SPMS 
(N= 2) 
 .428 (79) .670 
Gender Female = 
29 
Male = 12 
 Female = 
35 
Male = 5 
 3.433 (1)
 
 .064 
Ethnicity White= 33 
Black=5 
Hispanic/L
atino=2 
Asian 
Pacific 
Islander=1 
 White= 
34 
Black=2 
Hispanic/
Latino=4 
Asian 
Pacific 
Islander=
0 
 2.955(3) .399 
Note. 
a
 Equal variances not assumed. 
RRMS = Relapsing Remitting MS; SPMS = Secondary Progressive MS 
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Association between overweight/obesity and cognition, physical function, depression, 
anxiety, and stroke risk factors (Aim 1) 
Partial correlations were conducted in SPSS with age as a covariate to examine the 
relationship between excess body weight and cognitive function, physical function, and 
emotional function. Z-score composite variables of cognitive measures (SDMT, COWAT, 
RAVLT delay, MFIS cognitive subscale) and physical measures (Sway Balance Total, 
Average 25 foot walk, PDDS, MFIS physical fatigue subscale) were created.  Depression and 
anxiety scores were entered in separately. There was a significant relationship between 
WTHR, BMI and depression such that those with a higher WTHR and BMI reported more 
depression. However, no significant correlations were found between WTHR, BMI and the 
cognitive composite, physical composite, or anxiety. We also included patients’ total score 
on the Stroke Risk survey because it assesses a range of health behaviors and health 
conditions associated with obesity (e.g. blood pressure, regularity of heartbeat, cholesterol, 
exercise, family history of stroke, diabetes, tobacco use, body weight)(Kopelman, 2007). 
Research has demonstrated that such cerebrovascular and cardiovascular risk factors are 
associated with increased lesion load, brain atrophy and adverse mobility 
functioning(Kappus et al., 2015). Higher WTHR and BMI were both associated with 
increased stroke risk. More stroke risk factors were associated with worse physical function 
and depression.  
 
 
 
 
 
 
 
 
  
55 
 
Table 4 
Partial correlations of WTHR and BMI with cognitive, physical, and emotional function 
controlling for age 
 
 WTHR BMI Stroke 
Risk 
Cognitive Physical Depression Anxiety 
WTHR 1.000 .870
**
 .587** -.071 .157 .323
**
 .114 
BMI .870
**
 1.000 .510** .075 .061 .241
*
 .098 
Stroke Risk .587** .510** 1.000 -.035 .353** .540** .184 
Cognitive -.071 .075 -.035 1.000 -.379
**
 -.213 -.093 
Physical  .157 .061 .353** -.379
**
 1.000 .423
**
 .120 
Depression .323
**
 .241
*
 .540** -.213 .423
**
 1.000 .543
**
 
Anxiety .114 .098 .184 -.093 .120 .543
**
 1.000 
Note: Partial Correlations used to control for age 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
Follow-up correlations: Association between stroke risk factors and physical 
functioning 
In our initial analysis, a higher risk for stroke was associated with worse physical 
function (r= .540; p<..01). Follow-up correlations with individual items from the physical 
composite revealed that a higher stroke risk score was associated with worse balance, more 
disability, and more physical fatigue (Table 5). We also conducted exploratory partial 
correlations to examine which stroke risk factors were most strongly related to the physical 
function composite and individual indices of physical function (Table 6). Heartbeat 
irregularity was associated with increased physical fatigue. Worse diabetes (i.e. blood sugar 
level) was associated with worse balance and more disability (PDDS). Worse cholesterol was 
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associated with worse balance. Less exercise was associated with more physical fatigue, and 
a family history of stroke was associated with increased physical fatigue.  
 Table 5 
Partial correlations of stroke risk factors with measures of balance, walking speed, 
disability, and physical fatigue controlling for age 
 
Stroke 
Risk 
WTHR BMI 
Physical 
Composite 
Sway 
Total 
Balance 
Average 
Walk 
PDDS 
MFIS 
Physical 
Fatigue 
Stroke Risk 1.000 .593** .515** .363** -.356** .085 .304** .455** 
WTHR .593** 1.000 .871
**
 .178 -.151 .031 .159 .247
*
 
BMI .515** .871
**
 1.000 .076 -.084 -.024 .053 .139 
Physical 
Composite 
.363** .178 .076 1.000 -.876
**
 .730
**
 .914
**
 .801
**
 
Sway Total 
Balance 
-
.356** 
-.151 -.084 -.876
**
 1.000 -.531
**
 -.783
**
 -.600
**
 
Average 
Walk 
.085 .031 -.024 .730
**
 -.531
**
 1.000 .555
**
 .347
**
 
PDDS .304** .159 .053 .914
**
 -.783
**
 .555
**
 1.000 .700
**
 
MFIS 
Physical 
Fatigue 
.455** .247
*
 .139 .801
**
 -.600
**
 .347
**
 .700
**
 1.000 
Note: 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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Table 6 
Partial correlations of individual stroke risk factors with physical function measures of 
balance, walking speed, disability, and physical fatigue controlling for age 
 Physical 
Composite 
Balance Average 
Walk 
PDDS 
Disability 
Physical 
Fatigue 
Stroke Risk Total .363
**
 -.356
**
 .085 .304
**
 .455
**
 
Blood Pressure .164 -.175 .148 .090 .132 
Heart Beat 
Irregularity 
.184 -.188 .020 .103 .295
**
 
Diabetes .164 -.226
*
 .004 .236
*
 .081 
Cholesterol .169 -.265
*
 -.030 .162 .166 
Lack of Exercise .185 -.097 .075 .169 .270
*
 
Weight .139 -.130 -.004 .163 .171 
Stroke in family .176 -.181 .006 .128 .267
*
 
Note: 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
Association between overweight/obesity and MS specific health beliefs, dieting beliefs, 
and barriers to diet and exercise (Aim 2) 
To examine the relationship between excess body weight and barriers to diet and 
exercise, dieting beliefs scale (WLOC), and beliefs about the impact of health 
behaviors on MS symptoms and progression (MS Specific Health Beliefs), partial 
correlations were conducted in SPSS with age as a covariate. Higher WTHR and BMI 
were associated with increased barriers to diet and exercise. However, no significant 
correlations were found between WTHR, BMI and weight locus of control and MS 
specific health beliefs. Those with higher risk scores for stroke endorsed less belief that 
health behaviors could improve MS symptoms and progression (r=-.379; p<.01. See 
Table 7). 
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Table 7 
Partial Correlations of WTHR and BMI with barriers, dieting beliefs, and MS specific 
health beliefs controlling for age 
 
 
 WTHR BMI Stroke 
Risk 
Dieting 
Beliefs 
MS Health 
Beliefs 
Barriers 
Exercise 
Barriers 
Diet 
WTHR 
 
1.000 .871
**
 .604** -.075 -.135 .328
**
 .331
**
 
BMI 
 
.871
**
 1.000 .527** -.080 -.048 .303
**
 .327
**
 
Stroke 
Risk 
 
.604** .527** 1.000 -.171 -.379** .194 .160 
Dieting 
Beliefs 
 
-.075 -.080 -.171 1.000 .095 -.164 -.154 
MS 
Health 
Beliefs 
 
-.135 -.048 -.379** .095 1.000 -.131 .043 
Barriers 
Exercise 
 
.328
**
 .303
**
 .194 -.164 -.131 1.000 .621
**
 
Barriers 
Healthy 
Diet 
.331
**
 .327
**
 .160 -.154 .043 .621
**
 1.000 
Note: 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
Beliefs about the impact of weight on symptom severity (Aim 3) 
 For the Body Size and Symptoms task (BSS), participants were asked to rate the 
hypothetical severity of several symptoms on a Likert-type scale that ranged from zero (no 
issues) to six (severe problems) for three different body silhouettes (body 1= underweight, 
body 4= healthy weight, body 9= obese) (Appendix 1).  
 Preliminary analyses showed that current symptom expression, not participant weight 
status, was significantly related to symptom rating on the BSS. Therefore, mixed-factor 
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repeated measures ANOVAs using current symptoms as the between subjects factor were 
used to explore within-subject and between-group differences in predicted symptom severity 
for the modified fatigue impact scale short-form (MFIS) and other symptoms (e.g. mental 
fatigue, cognitive fatigue, walking speed, balance, anxiety, depression, and memory) at body 
silhouettes 1, 4, and 9. Examination of histograms and frequency statistics were used to 
create two equal categorical groups. The mixed-factor ANOVAs revealed significant main 
effects for the MFIS and each symptom on rated symptom severity at each body silhouette. 
This indicates that participants predicted each symptom would significantly change based on 
body weight gain or loss. Mean symptom ratings indicated that participants predicted the 
worst severity at an obese body weight (silhouette 9) and the best severity at a healthy body 
weight (silhouette 4). There were significant interactions between group membership (lower 
vs. higher current symptoms) and rating of the various silhouettes for MFIS, physical fatigue, 
walking speed, balance, anxiety, and depression, but not memory or mental fatigue. These 
interactions revealed that those with higher current symptoms predicted higher symptom 
severity for all silhouettes relative to participants who had fewer current symptoms. The 
magnitude of the different ratings between groups was greatest for silhouettes 1 and 4 
(Figures 1-8) and reduced for silhouette 9 for symptoms with significant interactions. Table 8 
shows means and standard deviations of symptom ratings at each silhouette. Tables 9-10 
show within and between subject ANOVA statistics which demonstrate significant between-
group differences for every symptom. Follow-up t-tests were conducted to determine where 
group differences existed (Table 11). These analyses indicated that overall patients with 
higher current symptoms reported higher symptom severity at silhouettes 1, 4, and 9, than 
patients with lower current symptoms. However, there were no group differences on ratings 
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of walking speed, anxiety, and MFIS fatigue severity for silhouette 9. Pairwise comparisons 
showed significant differences in symptom ratings between all silhouettes for each symptom 
such that the ratings for silhouette 1 were significantly different than silhouette 4 and 9, and 
ratings for silhouette 4 were significantly different than silhouette 9.  
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Table 8 Mean predicted symptom severity at various body silhouettes 
  
 
 Measure   M         SD  
MFIS 
Silhouette 1 (Underweight) 
9.66 5.35 
Silhouette 4 (Healthy Weight) 
7.92 4.64 
Silhouette 9 (Obese) 
16.22 2.90 
Mental 
Fatigue 
Silhouette 1 (Underweight) 
3.09 1.94 
Silhouette 4 (Healthy Weight) 
2.30 1.50 
Silhouette 9 (Obese) 
4.15 1.73 
Physical 
Fatigue 
Silhouette 1 (Underweight) 
2.98 2.02 
Silhouette 4 (Healthy Weight) 
2.25 1.48 
Silhouette 9 (Obese) 
5.37 .941 
Walking 
Speed 
Silhouette 1 (Underweight) 
2.20 1.89 
Silhouette 4 (Healthy Weight) 
2.02 1.62 
Silhouette 9 (Obese) 
5.16 1.18 
Balance 
Silhouette 1 (Underweight) 
2.32 1.92 
Silhouette 4 (Healthy Weight) 
2.17 1.65 
Silhouette 9 (Obese) 
4.78 1.43 
Anxiety 
Silhouette 1 (Underweight) 
2.35 1.99 
Silhouette 4 (Healthy Weight) 
   1.63 1.61 
Silhouette 9 (Obese) 
4.23 1.91 
Depression 
Silhouette 1 (Underweight) 
2.33 2.04 
Silhouette 4 (Healthy Weight) 
1.75 1.68 
Silhouette 9 (Obese) 
4.67 1.70 
Memory 
Silhouette 1 (Underweight) 
2.57 1.73 
Silhouette 4 (Healthy Weight) 
2.32 1.66 
Silhouette 9 (Obese) 
3.38 1.74 
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Table 9 
Main effect of body silhouette on rating of MS symptom severity among patients with 
low and high current symptom severity 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: MFIS= Modified Fatigue Impact Scale 
 
  
 
 
Measure 
 
Within Subjects 
Main Effect 
 
 
F(df)           P 
 
Within Subjects 
Interaction  
Main Effect*Group 
 
F(df)           P 
MFIS 157.67 
(1.90,149.89) 
.000 12.45 
(1.90,149.
89) 
.000 
Mental 
Fatigue 
51.03 (2,79) .000 .014 (2,79) .986 
Physical 
Fatigue 
133.77 (1.76, 
136.99) 
.000 .377 (1.76, 
136.99) 
.031 
Walking 
Speed 
177.64 (2, 79) .000 9.70 (2, 
79) 
.000 
Balance 136.62 (1.92, 
151.49) 
.000 3.44 (1.92, 
151.49) 
.036 
Anxiety 88.14 (1.91, 
264.37) 
.000 5.65 (1.91, 
264.37) 
.005 
Depression 93.57 (1.91, 
150.98) 
.000 3.61 (1.91, 
150.98) 
.031 
Memory 20.64 (2,79) .000 1.06 (2,79) .349 
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Table 10 
Between subject effects of body silhouette on symptom severity rating among patients with 
low and high current symptom severity 
 
 
 
Measure 
 
Between Group 
ANOVA 
Current Symptom 
 
F(df)           P 
MFIS 41.70 (1, 79) .000 
Mental Fatigue  51.25 (1, 79) .000 
Physical Fatigue 24.56 (1, 79) .000 
Walking Speed 36.77 (1, 79) .000 
Balance 44.06 (1, 79) .000 
Anxiety 19.64 (1, 79) .000 
Depression 29.57 (1, 79) .000 
Memory 31.16 (1, 79) .000 
 
Table 11 
Differences in symptom severity rating across silhouettes among patients with low and 
high current symptom severity 
 
 Silhouette 1 Silhouette 4 Silhouette 9 
 t (df) p t (df) p t (df) p 
Mental 
Fatigue 
-4.83 (79) .000 -6.67 (79) .000 -5.29 (59.1)
a
 .000 
Physical 
Fatigue 
-2.6 (78) .011 -5.82 (78) .000 -2.57 
(67.07)
a
 
.012 
Walking 
Speed 
-5.06 (79) .000 -6.16 (79) .000 -1.74 
(75.75)
a
 
.086 
Balance -4.94 (79) .000 -6.56 (79) .000 -3.38 
(56.05)
a
 
.001 
Memory -4.84 (79) .000 -5.14 
(45.64)
a
 
.000 -3.69 (79) .000 
Depression -3.6 (79) .001 -6.57 (79) .000 -2.2 (79) .031 
Anxiety -2.64 (79) .01 -7.71 
(54.24)
a
 
.000 -1.81 (79) .074 
MFIS Fatigue -4.89 (79) .000 -7.13 (79) .000 -1.86 (79) .067 
Note: a = Equal variances not assumed.  
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Figure 1. Mean ratings of fatigue at silhouettes 1, 4, and 9 among patients with low and high 
current fatigue 
 
 
 
Figure 2. Mean ratings of mental fatigue at silhouettes 1, 4, and 9 among patients with low 
and high current mental fatigue 
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Figure 3. Mean ratings of physical fatigue at silhouettes 1, 4, and 9 among patients with low 
and high current physical fatigue 
 
 
 
Figure 4. Mean ratings of walking speed impairment at silhouettes 1, 4, and 9 among patients 
with low and high current walking impairment 
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Figure 5. Mean ratings of balance impairment at silhouettes 1, 4, and 9 among patients with 
low and high current problems with balance 
 
 
 
Figure 6. Mean ratings of memory impairment at silhouettes 1, 4, and 9 among patients with 
low and high current memory impairment 
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Figure 7. Mean ratings of depression at silhouettes 1, 4, and 9 among patients with low and 
high current depression 
 
 
 
Figure 8. Mean ratings of anxiety at silhouettes 1, 4, and 9 among patients with low and high 
current anxiety 
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Impact of overweight/obesity on willingness to exercise for multiple sclerosis symptom 
improvement (Aim 4) 
 For the Exercise Willingness Task (EWT), participants were asked to provide the 
number of minutes of exercise they would be willing to do in order to achieve a hypothetical 
percentage (5%- 99%) of improvement in several symptoms common to MS (mental fatigue, 
physical fatigue, walking speed, balance, mood, memory, and overall quality of life) 
(Appendix C).  
 A principal components analysis was conducted to determine potential factors for the 
various symptoms contained within the EWT. The PCA revealed that the questionnaire is 
unitary and that the items have good validity. Therefore, we opted to average the minutes 
patients reported willing to exercise for each symptom (mental fatigue, physical fatigue, 
walking speed, balance, mood, memory) at each percentage of improvement (5%, 10%, 25%, 
34%, 50%, 66%, 75%, 90%, 99%).  
 Two mixed-factor ANOVAs were performed to examine willingness to engage in 
exercise for a hypothetical percentage of symptom improvement at two time points: 
immediate and delayed. The average number of minutes an individual was willing to exercise 
to achieve a specific percentage of improvement (5%-99%) was entered into the analysis. 
Preliminary analyses showed that current symptom severity, but not weight, was related to 
exercise willingness. Therefore, current symptom severity was used as the between subjects 
factor in the analysis. Current symptom severity was calculated as the average of current 
symptom severity ratings. Examination of histograms and frequency statistics were used to 
create two equal categorical groups.  
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Immediate and Delayed Results 
 See Tables 12-14 for average reported minutes of exercise at each exercise percentage 
and Mixed-Factor ANOVA results. There was a significant main effect of minutes of 
exercise across percentage of improvement for both immediate and delayed symptom 
improvement. This indicated that willingness to exercise to improve symptoms increased as 
the percentage of benefit increased. There were significant differences between groups 
(higher and lower symptom severity) in willingness to exercise. Follow-up t-tests were 
conducted to examine differences in exercise willingness between patients with low and high 
current symptoms (Table 15). Additionally, there were significant interactions in exercise 
willingness based on group membership. These showed that patients with higher levels of 
symptom severity reported greater willingness to exercise overall, and, as percentage of 
improvement increased, group differences in exercise willingness broadened (Figures 9-10).  
Pairwise comparisons showed significant differences in between all amounts of exercise 
willingness at each level of hypothetical improvement.  
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Table 12 
Means and standard deviations of exercise willingness to improve symptoms 
immediately and in 5 years among MS patients  
 Percentage of 
Improvement 
Immediate Delayed 
M SD M SD 
5% 10.6313 24.56719 9.8203 16.27977 
10% 14.9547 32.71548 12.8031 18.86754 
25% 21.1578 35.36351 18.6359 23.90630 
34% 26.8766 41.55916 21.8938 26.03822 
50% 33.4750 44.51778 28.8141 34.59899 
66% 39.3266 47.97595 31.9438 36.37868 
75% 46.8938 52.83401 38.9859 44.08333 
90% 53.1906 55.47951 44.4188 48.36530 
99% 59.7031 63.96918 50.9453 54.55469 
 
Table 13 
Mixed-factor ANOVA within-subject effects of exercise willingness to improve 
symptoms among patients with low and high current symptom severity 
 
 
Measure 
 
 
Within Subjects 
Main Effect 
 
F(df)           P 
 
 
Interaction  
Main Effect*Group 
 
F(df)           P 
Immediate 
Symptom 
Improvement 
88.20 
(1.64,12
4.29) 
.000 3.36  
(1.64,124.
29) 
.047 
Delayed 
Symptom 
Improvement 
103.47  
(1.49, 
114.97) 
.000 581 (1.49, 
114.97) 
.008 
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Table 14 
Mixed-factor ANOVA between subjects effects of exercise willingness to improve 
symptoms among patients with low and high current symptom severity 
 
 
Measure 
 
 
Between Group ANOVA 
Current Symptom 
 
F(df)           P 
Immediate 
Improvement 
6.20 (1, 76) .015 
Delayed 
Improvement 
7.64 (1, 77) .007 
 
Table 15 
T-tests to examine differences in exercise willingness at various hypothetical levels of 
improvement among patients with low and high current symptom severity 
Improvement 
Percentage 
Immediate Delayed 
 t (df) p t (df) p 
5% -2.07 
(66.06)*  
.042 -2.02 (66.94)* .047 
10% -2.13 (77) .036 -2.11 (77) .038 
25% -1.67 (77) .099 -2.01 (77) .048 
34% -2.01 (77) .048 -2.13 (77) .036 
50% -2.02 (77) .047 -2.25 (77) .027 
66% -2.27 (77) .026 -2.16 (77) .034 
75% -2.29 (77) .025 -3.01 (77) .004 
90% -2.07 (77) .042 -2.94 (77) .005 
99% -2.12 (77) .037 -3.09 (59.52)* .003 
 Note: *= equal variances not assumed 
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Figure 9. Number of minutes patients with low and high current symptoms reported willing 
to exercise to improve symptoms immediately  
 
 
 
Figure 10. Number of minutes patients with low and high current symptoms reported willing 
to exercise to improve symptoms in 5 years 
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CHAPTER 5 
DISCUSSION 
Importance 
 High rates of obesity lead to increased risk for several life-threatening health 
conditions including type II diabetes and metabolic syndromes, hypertension, heart disease, 
stroke, certain types of cancer, gout, sleep apnea, obesity hypoventilation syndrome, asthma, 
gallbladder problems, osteoarthritis, stress fractures, reproductive problems, and numerous 
autoimmune diseases(Kopelman, 2007). Rates of obesity among patients with MS have been 
shown to be as high or higher than the general population (Matarese et al., 2010; Munger et 
al., 2009) and some researchers speculate that there is a link between higher levels of leptin 
and cascades of increased inflammation and eventual neuronal destruction in MS(Matarese et 
al., 2010; Matarese et al., 2008).  
 Both MS and obesity are individually linked to debilitating symptoms and their 
negative effects together may be exponential in furthering MS disease progression(Matarese 
et al., 2010; Matarese et al., 2008). Therefore, research on the perceived and objective impact 
of obesity on MS symptoms and progression is warranted. Studies that have examined 
objective functional differences between healthy weight and overweight MS patients show 
inconsistent results. Some studies have shown that obesity is related to increased lesion 
load(Kappus et al., 2015), risk of ambulatory disability(R. A. Marrie et al., 2010), 
fatigue(Weiland et al., 2015) and depression(Cambil-Martín et al., 2014; Taylor et al., 2014), 
while others have shown no differences in physical function and ambulatory mobility (Pilutti 
et al., 2012) or fatigue(Trojan et al., 2007). No research has examined the association 
between obesity and cognitive function among patients with MS. Furthermore, there is a lack 
  
74 
 
of knowledge surrounding patient beliefs about the impact of weight on MS symptoms. To 
date, no research has examined MS patient beliefs about how weight gain/loss impacts 
symptom severity or how MS patients make hypothetical cost-benefit health behavior 
decisions.  By understanding how patients think weight impacts MS symptoms and their 
willingness to endure a cost (e.g. exercise) to receive a benefit (e.g. symptom reduction), we 
may be able to develop individualized interventions that increase motivation to improve 
health behaviors that that lead to reduced symptoms and improved quality of life.  
 The purpose of this study was to determine if healthy weight and overweight/obese 
patients with MS differ in cognitive, physical, and emotional function, and beliefs about 
health and barriers to diet and exercise. We also sought to examine patient beliefs about the 
negative impact of weight gain on symptom severity, and to explore patient willingness to 
exercise for hypothetical symptom improvement.  
Impact of obesity on physical, emotional, and cognitive function (Aim 1) 
We hypothesized that having a healthy weight would be associated with better 
performance on measures of physical, emotional, and cognitive function. Age was entered 
into the analyses as a covariate. Consistent with our hypotheses, lower WTHR and lower 
BMI were both associated with lower levels of depression. Contrary to our hypotheses, 
excess body weight was not associated with cognition, physical function or anxiety. In 
contrast, a higher number of stroke risk factors was associated with poorer physical 
functioning (r= .353; p< .01) and higher levels of depression in MS (r= .540; p <.01).  
Surprisingly, excess body weight was not associated with physical functioning. 
However, an increased number of stroke risk factors was associated with worse balance (r= -
.356; p <.01), increased disability (r= .304; p <.01), and higher levels of physical fatigue (r= 
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.455; p <.01). This may indicate that it is not carrying excess weight per se, that negatively 
impacts physical functioning, but instead the combination of several health factors and 
behavioral choices associated with obesity. Research shows conflicting data on the impact of 
body weight on physical function. It is possible that certain cardiovascular and 
cerebrovascular consequences mediate the impact of weight on overall physical function. As 
noted above, several studies have found conflicting results when examining the relationship 
between obesity and physical functioning in MS patients. These conflicting findings may be 
due in part to the presence or absence of stroke risk factors in disparate study samples (R. A. 
Marrie et al., 2015) as past research has demonstrated worse lesion load and risk for 
ambulatory disability with increasing cardiovascular risk factors(Kappus et al., 2015). Future 
studies should examine which combination of factors (ex. blood pressure, heart beat 
regularity, diabetes, cholesterol, exercise,) account for the heterogeneous relationship 
between body weight and physical functioning. These factors may be especially important 
when discussing the impact of obesity on physical function in patients with MS, as prior 
research shows that MS patients have higher rates of vascular comorbidities than the general 
population(R. A. Marrie et al., 2015). 
We examined follow-up partial correlations using age as a covariate to examine 
which individual stroke risk factors were related to variables of physical function. Heartbeat 
irregularity was associated with increased physical fatigue (r= .295; p <.01). Diabetes (i.e. 
blood sugar level) was associated with worse balance (r= -.226; p <.05) and more disability 
(PDDS) (r= .236; p <.05). Elevated cholesterol was associated with worse balance (r= -.265; 
p <.01). Less exercise was associated with more physical fatigue (r= .270; p <.05), and a 
family history of stroke was associated with increased physical fatigue (r= .267; p <.05).  
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These results are consistent with past research that shows clustering of negative 
health conditions among patients with chronic disease(Bernstein, Wajda, & Blanchard, 2005; 
Vogeli et al., 2007). That is, the more negative health conditions a person has, the more 
likely they are to develop health problems. For example, consistent with our study, research 
has demonstrated that diabetes is associated with poorer physical function. Processes 
associated with poorly regulated blood sugar, such as neuropathy, cardiorespiratory capacity, 
or sub-clinical cardiovascular disease, also contribute to worse disability and a higher risk for 
falling due to negative effects of unregulated blood sugar on cardiorespiratory capacity, 
balance, dizziness, general weakness, muscle cramps and blurred vision (Gregg et al., 2000; 
Najafi, Bharara, Talal, & Armstrong, 2012; Ryerson et al., 2003). Such processes may also 
set the stage for other chronic health conditions and research has shown that multiple chronic 
conditions can, at times, interact and cause synergistic functional impairment(Fultz, Ofstedal, 
Herzog, & Wallace, 2003). Patients with MS may be especially prone to developing other 
chronic conditions because of the inflammatory nature of the disease(Bernstein et al., 2005). 
Taken together, the results of our study, along with past research, highlight an important role 
for educational intervention among patients with multiple negative health conditions. Patients 
may not realize the interaction that several negative health behaviors and/or conditions may 
have with one another and may benefit from interventions that target risk factors for multiple 
chronic conditions. Physical activity, diabetes, and cholesterol can be addressed through 
behavioral intervention. Diabetes management may be especially important for patients with 
MS because of its relationship to physical and motor dysfunction which is also precipitated 
by the MS disease process. A healthy diet designed to manage and lower cholesterol is also 
consistent with nutrition guidelines for MS patients that recommend  a diet low in saturated 
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fats (i.e. proinflammatory fats)(Zhang, Willett, Hernán, Olek, & Ascherio, 2000). Previous 
research has also demonstrated positive effects of exercise on cardiovascular and 
cerebrovascular risk factors, inflammation, and MS fatigue(Fulcher & White, 1997; Latimer-
Cheung, Pilutti, et al., 2013; McCullagh, Fitzgerald, Murphy, & Cooke, 2008; Nicklas, You, 
& Pahor, 2005). Patients whose treatments target underlying risk factors for other chronic 
diseases and comorbid conditions may experience improved long-term outcomes relative to 
those whose treatments only consider MS. 
Higher levels of depression and anxiety exist in both MS and obese persons relative 
to the general population(Jones et al., 2012; Siegert & Abernethy, 2005). However, some 
research indicates that obese patients experience higher lifetime levels of depression than 
anxiety(Zhao et al., 2009). Other research has found depression to be more highly associated 
with worse health behaviors than anxiety(Bonnet et al., 2005). Our study found that 
depression, but not anxiety, was associated with excess body weight in MS. Depression may 
compound the negative effects of fatigue and physical disability by further reducing 
motivation and energy to engage in health behaviors that have the capacity to maintain a 
healthy and stable body weight(Bakshi, Shaikh, et al., 2000; Kroencke, Lynch, & Denney, 
2000). That there is a strong relationship between depression and fatigue such that those with 
higher levels of depression experience higher levels of fatigue (Bakshi, Shaikh, et al., 2000). 
Interventions to help patients cope with psychological aspects of chronic disease may have 
beneficial implications for both depression and MS fatigue.  
Our study did not find significant associations between excess body weight and 
cognitive function. Some past research has indicated that there is an association between 
increased BMI and reduced cognitive function(Gunstad et al., 2007). Cognitive problems 
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caused by obesity may be relatively small compared to those caused by MS and thus, a very 
large sample size would be needed to detect an effect. It is also plausible that differences in 
cognitive function due to obesity may be unmasked at a later point in disease progression 
with greater disability. Specifically, the impact of obesity on cognitive function may not yet 
be detectable as we included patients who primarily had a diagnosis of RRMS and generally 
lower levels of disability (PDDS ≤5). The effect of obesity on these capabilities may 
compound over time and may be best studied in patients with greater disability and 
progressive forms of MS. It is also possible that a much larger sample of extreme obesity 
may provide greater power to detect differences between groups. 
Impact of obesity on MS specific health beliefs, dieting beliefs, and barriers to 
healthy diet and exercise (Aim 2) 
We hypothesized that excess body weight would be associated with increased barriers 
to exercise and a healthy diet and also reduced belief in one’s ability to positively impact 
their MS and control body weight (Dieting Beliefs Scale). When controlling for age, excess 
body weight was associated with increased barriers to exercise and eating a healthy diet. 
However, there were no significant associations between excess body weight and belief in 
one’s ability to control his/her weight or MS specific health beliefs.  Our results indicated 
that both healthy weight and overweight/obese MS patients hold similar beliefs about weight 
and weight loss that reflect an internal locus of control. Likewise, participants perceived an 
association between health behaviors (i.e. eating healthy and exercise) and the potential for 
improvement in MS symptoms and progression.  These results are promising and indicate 
that MS patients endorse the belief that weight can be managed by the individual and that 
health behaviors can be used to positively impact MS. A higher WTHR was associated with a 
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larger number of barriers to diet and exercise. Previous research has shown a relationship 
between higher BMI and increased barriers to health behaviors (Sharifi, Mahdavi, & 
Ebrahimi-Mameghani, 2013). Interventions which aim to reduce barriers to exercise and 
healthy eating may be imperative to facilitate health behavior change among patients who are 
overweight and have MS, as these two conditions often carry increased barriers to health 
behaviors. For example, patients may benefit from programs that emphasize small amounts 
of progress over sweeping changes (i.e. “5 minutes is better than zero minutes”) and that 
teach them ways to exercise from home. Simple exercises that don’t require expensive 
equipment or complex motor coordination may be especially suited to patients with MS. 
Dietary interventions that teach strategies to reduce fatigue while cooking could be 
paramount to improving patient dietary habits. For example, patients may benefit from 
learning simple recipes that can be prepared throughout the day, recipes that can be prepared 
and frozen in advance, grocery delivery services, or from modifications to kitchen work 
spaces (i.e. lowered tables,  kitchen tools that require less strength and force). Importantly, 
interventions should strive to balance the disability of the individual while also promoting 
active engagement in health improvement.  
Explore patient beliefs about the impact of weight on MS symptoms and fatigue 
(Aim 3) 
We sought to explore perceived associations between various body weights and 
symptom severity, including MFIS fatigue using the BSS task. Current symptom severity 
was used as the between subjects factor. On the BSS task, MS patients predicted that 
symptoms would significantly change based on weight gain or loss. Mean symptom ratings 
indicated that )participants predicted the worst severity at an obese body weight (silhouette 9) 
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and the best severity at a healthy body weight (silhouette 4). There were significant 
interactions based on group membership (low and high symptom severity) and ratings for the 
3 silhouettes on symptoms of MFIS fatigue, physical fatigue, walking speed, balance, 
anxiety, and depression. Examination of these interactions generally showed that those with 
higher current symptom severity perceived higher symptom severity at the different 
silhouettes relative to patients with lower current symptom severity; the magnitude of this 
difference was greatest for silhouettes 1 and 4. It may be that patients with worse current 
symptoms have less hope that symptoms could be improved through weight loss which may 
reduce motivation to increase health behaviors.  
These results confirm that MS patients perceive a link between weight gain/loss and 
change in symptom severity. However, these results do not illuminate reasons why many MS 
patients maintain an unhealthy weight if they also believe that obesity is related to worse MS 
symptoms. Interaction analyses showed that patients with higher current symptoms 
hypothesized less symptom improvement with weight loss than patients with lower current 
symptoms. This illuminates a need for research on the specific gains that patients can expect 
in symptom improvement if they lose various percentages of excess body weight. The ability 
to provide patients with reasonable expectations would be highly valuable in the 
development of tailored weight loss programs. Patients may also benefit from interventions 
which emphasize the link between weight, diet, exercise, and inflammation. Such future 
research with this added information may be used to harness and strengthen the perceived 
association between weight and worsened MS symptoms to subsequently produce changes in 
health behaviors that may result in improved outcomes during the disease course.  
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Explore predicted willingness to engage in exercise for a hypothetical symptom 
improvement (Aim 4) 
We also sought to explore MS patient willingness to endure a cost (exercise) to 
achieve a hypothetical gain (symptom improvement) using the EWT.  As expected, MS 
patients reported significantly increased willingness to exercise for a longer period of time as 
the hypothetical percentage of symptom improvement increased. This was consistent for both 
immediate and delayed improvements. The analysis of exercise to achieve immediate 
improvement revealed a significant interaction between group (higher versus lower current 
symptoms) and reported minutes of exercise at various percentages. Specifically, we found 
that patients with higher symptoms reported greater minutes of exercise willingness relative 
to patients with lower current symptoms and this difference increased as the percentage of 
hypothetical improvement increased.  Future studies that target improving motivation for 
health behavior change when symptoms are less severe may improve patient outcomes as 
their disease progresses.  
Exercise can improve hypertension, insulin resistance, glucose intolerance and high 
density lipoprotein levels (P. D. Thompson, 2003). Prevention and improvement of 
comorbidities such as diabetes, hypertension, hyperlipidemia, cardiovascular disease and 
cerebrovascular disease may require extra attention within the MS population due to the 
specific physical, cognitive, and psychological complications associated with MS.  In 
addition to general comorbidities, past research has demonstrated that autoimmune diseases 
carry an increased risk of vascular disease that cannot be explained fully by traditional risk 
factors. Researchers speculate that inflammatory processes are risk factors in and of 
themselves for vascular comorbidities which result in several negative health outcomes (R. 
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A. Marrie et al., 2015). Furthermore, MS patients, even in the earlier stages of disease, have 
been shown to exercise less, use more tobacco, and be more overweight than the general 
population (R. A. Marrie et al., 2015).  This indicates that patients with MS may have 
additional behavioral and physiological hurdles standing in the way of optimal health. Future 
methods which help patients engage in preventative strategies, especially during the early 
disease process, may be tantamount to improving long-term progression and symptom 
expression.  
No previous studies have examined MS patient willingness to exercise (or engage in 
health behaviors) to achieve health benefits. We found that patients’ reasoning followed a 
logical progression such that patients were willing to exercise more as the amount of benefit 
increased. These results are promising as they indicate that patients are able to engage in 
planning health behavior interventions in a meaningful and logical way. Patients may be 
especially motivated by real-world data on the amount of improvement that can be 
reasonably expected from exercise interventions. This is similar to how patients make cost-
benefit decisions about medications. For example, patients often want to how much 
medication will lead to improvement and what side effects to expect before making a 
decision to begin taking medication. This information is readily available for many 
medications, but little, if any, information regarding the amount of clinically significant 
improvement that will result from weight loss interventions or exercise is provided to 
patients(Latimer-Cheung, Pilutti, et al., 2013). More often, patients are told that they will 
likely see gains in functional abilities, strength, mobility, etc(Latimer-Cheung, Martin Ginis, 
et al., 2013; Latimer-Cheung, Pilutti, et al., 2013). This lack of specificity may reduce 
motivation or belief that exercise may be an important component of symptom improvement. 
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Future studies should garner data on the average amount of symptom improvement patients 
experience with different types and amounts of exercise. By understanding what kind and 
how much improvement patients require to maintain motivation for exercise, researchers may 
be better able to design tailored interventions and provide patients with reasonable and 
achievable expectations for improvement. This kind of shared decision making may help 
patients make decisions about what types and what amounts of exercise they would be 
willing to do for typical benefits experienced by patients with similar health problems. Such 
future studies may increase patient adherence to interventions and long-term health 
behaviors.  
Although the preliminary results were promising and participants’ answers followed a 
logical progression, it is unclear to what extent these results would hold in a real-life 
scenario. Previous research indicates that follow-through on intention for health behaviors is 
poor as a high proportion of individuals are poorly compliant to medications, weight loss 
regimens, smoking cessation, and other forms of health behavior change(Haynes, McDonald, 
& Garg, 2002). Even with the known benefits of exercise, most individuals do not meet the 
guidelines for minimal physical activity and often significantly overestimate the number of 
minutes of exercise they actually complete  (Messer, 2012) (Dyrstad, Hansen, Holme, & 
Anderssen, 2014). Therefore, it can be reasoned that patients in this study overestimated the 
true number of minutes they could feasibly exercise on a consistent basis(Gomersall, Norton, 
Maher, English, & Olds, 2015). Patients may benefit from two types of information: 
(1)Information on how much exercise others of a similar health status are able to reliably 
complete on average, and (2)Information on the actual amount of exercise and health 
behavior change needed for specific amounts of symptom improvement. This may be used to 
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provide patients with realistic expectations and aid them in developing achievable goals that 
will result in measurable improvements in symptom severity.  
Furthermore, many participants reported this task to be cognitively taxing which may 
have reduced motivation to consider each symptom and percent-improvement item 
individually. Future studies should determine which symptoms patients would like to 
improve most and use this to customize interventions that optimize the potential for 
adherence. Despite these limitations, results of this task indicate that patients may be willing, 
or even enthusiastic, to participate in the planning of their own health behavior interventions 
when given quantitative information about possible associated health outcomes.    
Conclusions 
This was the first study to examine MS patient beliefs about the impact of excess 
body weight on disease symptoms and patient willingness to engage in exercise to experience 
proposed improvements in MS symptoms. Our results indicated that there is an association 
between depression and higher levels of obesity in MS. In addition, patients with more stroke 
risk factors exhibited poorer physical functioning. The BSS task showed that patients do 
perceive a link between their body weight and the severity of their symptoms. Furthermore, 
on the EWT patients reported increased willingness to exercise as the level of proposed 
benefit increased.   
The results of this study highlight that patients with MS perceive an association 
between their weight and symptom severity; also, patients are willing to consider enduring 
health behavior costs that result in MS symptom improvement. Notably, current rated 
symptom severity emerged in our analyses as an important moderator of body silhouette 
symptom rating (those with the worst current symptoms expected less improvement in 
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symptoms at a healthy weight or low body weight) and willingness to exercise for proposed 
benefit (those with the worst current symptoms reported greater willingness to exercise and 
this increased alongside the percentage of hypothetical improvement). This shows that those 
with the worst current symptoms may expect less benefit with weight loss, but also express 
greater willingness to exercise when high levels of benefit are sure. This reveals a need for 
future research that objectively examines clinically significant changes in symptom 
expression, symptom severity, disease progression, and lesion load following weight gain or 
loss.  Future studies may capitalize on these results by providing patients with data on what 
gains to expect for various health interventions. Interventions that provide this information 
may improve adherence by supporting patients in making logical decisions about the amount 
of health behavior change they are willing to endure to receive symptom improvement. Such 
tailored treatments may serve as a preventative strategy used to mitigate unnecessary 
physical, cognitive, and emotional decline associated with excess body weight. Capitalizing 
on prevention earlier in the disease course, when patients are most capable, is likely 
paramount to improving long-term outcomes for MS patients.  
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Appendix A 
Body Size and Symptoms Task 
 
Please write down what you think your symptoms would be if you were at body silhouettes 1, 4, 
and 9.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
No issues  Slight Problems  Moderate 
Problems  
 Severe 
Problems 
0 1       2        3 4 5 6 
 You at body 
silhouette 
#1 
You at body 
silhouette 
#4 
You at body 
silhouette #9 
 
Mental Fatigue    
Physical Fatigue    
Pain    
Balance    
Walking Speed    
Sleep Quality    
Memory    
Thinking Speed    
Depression    
Anxiety    
Disease 
Progression Speed 
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Appendix B 
 
Body Size and Symptoms Task- Fatigue 
 
Please fill out the following questionnaire based on how you believe you would feel at each 
of the listed body silhouettes. Starting with “silhouette 1” go down the column and fill in the 
number that you believe would correspond with how you’d feel if you were at each specified 
silhouette.  
 
 
 
 
 
 
 
 
 
  
 Silhouette #1 Silhouette #4 Silhouette #9 
 
 
I would have reduced 
alertness 
   
I would be limited in my 
ability to do things away from 
home 
   
I would have  trouble 
maintaining physical effort for 
long periods 
   
I would be less able to 
complete tasks that require 
physical effort 
   
I would have trouble 
concentrating 
   
Never Rarely Sometimes Often Almost Always 
0 1 2 3 4 
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Appendix C 
Exercise Willingness Task 
 
Sometimes it is hard to do things that are healthy for our bodies. It may seem like exercise and 
eating healthy don’t provide us with noticeable improvement in health. For this activity, let’s 
pretend that you know exercising will improve your MS symptoms by a certain percent. Please 
write down the number of extra minutes (beyond what you already do) you’d be willing to 
engage in strenuous exercise (the kind that makes your heart beat fast and makes you feel 
out of breath) EACH DAY to receive symptom reduction.  
We will do this exercise 2 times. On the first you will write down the minutes you’d be willing 
to exercise strenuously to improve your symptoms IMMEDIATELY. The next two will surround 
what you’re willing to do to achieve symptom improvement in 5 years without any current 
improvement.  
Strenuous exercise includes things that make your heart beat faster and make you feel out of 
breath. This could be things like running, climbing the stairs, weight lifting, hiking a mountain, 
using a cardio machine at the gym.  
Remember, try to imagine what it would feel like to have improvement in these areas of your 
life. You’re not being asked to add up the exercise per day for each symptom. Try to think of 
them separately. 
***Imagine what it would feel like to keep your heart rate up the entire time you’re exercising 
for this activity.  
Here’s an example:  
 33% 
improvement 
in symptoms 
66% 
improvement 
in symptoms 
90% 
improvement 
in symptoms 
100% 
improvement 
in symptoms 
Fatigue 10 15 30 60 
Walking 
Speed 
5 10 15 20 
Balance 5 15 20 30 
Mood 0 5 8 20 
Weakness 10 25 40 55 
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Write down the additional number of minutes you’d be willing to spend in strenuous exercise 
each day to achieve the hypothetical improvement in your symptoms IMMEDIATELY (alternate 
form: IN 5 YEARS).  
 Percent Symptom Improvement 
 <5%  10%  25% 34%  50% 66%  75% 90% >99%  
Mental 
Fatigue 
         
Physical 
Fatigue 
         
Walking 
Speed 
         
Balance  
 
        
Mood  
 
        
Memory  
 
        
 
 
 
 
 
 
 
  
  
90 
 
References 
Acheson, E. D., Bachrach, C. A., & Wright, F. M. (1960). Some comments on the relationship of the 
distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta 
Psychiatrica Scandinavica. Supplementum, 35(147), 132-147.  
Al Maskari, M. Y., & Alnaqdy, A. A. (2006). Correlation between Serum Leptin Levels, Body Mass 
Index and Obesity in Omanis. Sultan Qaboos University Medical Journal, 6(2), 27-31.  
Alonso, A., & Hernán, M. A. (2008). Temporal trends in the incidence of multiple sclerosis: A 
systematic review. Neurology, 71(2), 129-135. doi:10.1212/01.wnl.0000316802.35974.34 
Andajani-Sutjahjo, S., Ball, K., Warren, N., Inglis, V., & Crawford, D. (2004). Perceived personal, 
social and environmental barriers to weight maintenance among young women: A community 
survey. The International Journal of Behavioral Nutrition and Physical Activity, 1(1), 15. 
doi:10.1186/1479-5868-1-15 
Andrade, V. M., Bueno, O. F., Oliveira, M. G., Oliveira, A. S., Oliveira, E. M., & Miranda, M. C. 
(1999). Cognitive profile of patients with relapsing remitting multiple sclerosis. Arquivos de 
Neuro-Psiquiatria, 57(3B), 775-783.  
Arnett, P. A., Rao, S. M., Grafman, J., Bernardin, L., Luchetta, T., Binder, J. R., & Lobeck, L. (1997). 
Executive functions in multiple sclerosis: An analysis of temporal ordering, semantic 
encoding, and planning abilities. Neuropsychology, 11(4), 535-544.  
Arnett, P. A., & Strober, L. B. (2011). Cognitive and neurobehavioral features in multiple sclerosis. 
Expert Review of Neurotherapeutics, 11(3), 411-424. doi:10.1586/ern.11.12 
Ascherio, A. (2013). Environmental factors in multiple sclerosis. Expert Review of 
Neurotherapeutics, 13(12 Suppl), 3-9. doi:10.1586/14737175.2013.865866 
Ascherio, A., & Munger, K. L. (2007a). Environmental risk factors for multiple sclerosis. Part I: The 
role of infection. Annals of Neurology, 61(4), 288-299. doi:10.1002/ana.21117 
Ascherio, A., & Munger, K. L. (2007b). Environmental risk factors for multiple sclerosis. Part II: 
Noninfectious factors. Annals of Neurology, 61(6), 504-513. doi:10.1002/ana.21141 
Ascherio, A., & Munger, K. L. (2010). Epstein-barr virus infection and multiple sclerosis: A review. 
Journal of Neuroimmune Pharmacology, 5(3), 271-277. doi:10.1007/s11481-010-9201-3 
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., . . . Pohl, C. 
(2014). Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA 
Neurol, 71(3), 306-314. doi:10.1001/jamaneurol.2013.5993 
Ashwell, M., Gunn, P., & Gibson, S. (2012). Waist-to-height ratio is a better screening tool than waist 
circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-
analysis. Obesity Reviews, 13(3), 275-286. doi:10.1111/j.1467-789X.2011.00952.x 
Ashwell, M., & Hsieh, S. D. (2005). Six reasons why the waist-to-height ratio is a rapid and effective 
global indicator for health risks of obesity and how its use could simplify the international 
public health message on obesity. International Journal of Food Sciences and Nutrition, 
56(5), 303-307. doi:10.1080/09637480500195066 
Ashwell, M., Mayhew, L., Richardson, J., & Rickayzen, B. (2014). Waist-to-height ratio is more 
predictive of years of life lost than body mass index. PloS One, 9(9), e103483. 
doi:10.1371/journal.pone.0103483 
Association, N. S. (2015). Stroke Risk Scorecard. In. 
Bakshi, R., Czarnecki, D., Shaikh, Z. A., Priore, R. L., Janardhan, V., Kaliszky, Z., & Kinkel, P. R. 
(2000). Brain MRI lesions and atrophy are related to depression in multiple sclerosis. 
Neuroreport, 11(6), 1153-1158.  
Bakshi, R., Shaikh, Z. A., Miletich, R. S., Czarnecki, D., Dmochowski, J., Henschel, K., . . . Kinkel, 
P. R. (2000). Fatigue in multiple sclerosis and its relationship to depression and neurologic 
disability. Multiple Sclerosis, 6(3), 181-185. doi:10.1177/135245850000600308 
Banks, W. A., Coon, A. B., Robinson, S. M., Moinuddin, A., Shultz, J. M., Nakaoke, R., & Morley, J. 
E. (2004). Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes, 53(5), 
1253-1260.  
  
91 
 
Baughcum, A. E., Chamberlin, L. A., Deeks, C. M., Powers, S. W., & Whitaker, R. C. (2000). 
Maternal perceptions of overweight preschool children. Pediatrics, 106(6), 1380-1386.  
Benedict, R. H., Bruce, J. M., Dwyer, M. G., Abdelrahman, N., Hussein, S., Weinstock-Guttman, B., 
. . . Zivadinov, R. (2006). Neocortical atrophy, third ventricular width, and cognitive 
dysfunction in multiple sclerosis. Archives of Neurology, 63(9), 1301-1306. 
doi:10.1001/archneur.63.9.1301 
Benedict, R. H., Ramasamy, D., Munschauer, F., Weinstock-Guttman, B., & Zivadinov, R. (2009). 
Memory impairment in multiple sclerosis: Correlation with deep grey matter and mesial 
temporal atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 80(2), 201-206. 
doi:10.1136/jnnp.2008.148403 
Benedict, R. H., Smerbeck, A., Parikh, R., Rodgers, J., Cadavid, D., & Erlanger, D. (2012). 
Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: 
Implications for multiple sclerosis clinical trials. Multiple Sclerosis, 18(9), 1320-1325. 
doi:10.1177/1352458511435717 
Benito-León, J., Morales, J. M., & Rivera-Navarro, J. (2002). Health-related quality of life and its 
relationship to cognitive and emotional functioning in multiple sclerosis patients. European 
Journal of Neurology, 9(5), 497-502.  
Bernstein, C. N., Wajda, A., & Blanchard, J. F. (2005). The clustering of other chronic inflammatory 
diseases in inflammatory bowel disease: A population-based study. Gastroenterology, 129(3), 
827-836. doi:10.1053/j.gastro.2005.06.021 
Bethoux, F., & Bennett, S. (2011). Evaluating walking in patients with multiple sclerosis: Which 
assessment tools are useful in clinical practice? Int J MS Care, 13(1), 4-14. 
doi:10.7224/1537-2073-13.1.4 
Bishop, K. L. (2002). Longitudinal predictors of weight fluctuation in men and women. Dissertation 
abstracts international, 64, 1892-2046.  
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital Anxiety 
and Depression Scale. An updated literature review. Journal of Psychosomatic Research, 
52(2), 69-77.  
Blaak, E. (2001). Gender differences in fat metabolism. Current Opinion in Clinical Nutrition and 
Metabolic Care, 4(6), 499-502.  
Bonnet, F., Irving, K., Terra, J. L., Nony, P., Berthezène, F., & Moulin, P. (2005). Anxiety and 
depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. 
Atherosclerosis, 178(2), 339-344. doi:10.1016/j.atherosclerosis.2004.08.035 
Bosnar-Puretić, M., Basić-Kes, V., Jurasić, M. J., Zavoreo, I., & Demarin, V. (2009). The association 
of obesity and cerebrovascular disease in young adults: A pilot study. Acta Clinica Croatica, 
48(3), 295-298.  
Boström, I., Stawiarz, L., & Landtblom, A. M. (2013). Sex ratio of multiple sclerosis in the National 
Swedish MS Register (SMSreg). Multiple Sclerosis, 19(1), 46-52. 
doi:10.1177/1352458512446169 
Bougoulia, M., Triantos, A., & Koliakos, G. (2006). Effect of weight loss with or without orlistat 
treatment on adipocytokines, inflammation, and oxidative markers in obese women. 
Hormones (Athens), 5(4), 259-269.  
Braley, T. J., & Chervin, R. D. (2010). Fatigue in multiple sclerosis: Mechanisms, evaluation, and 
treatment. Sleep, 33(8), 1061-1067.  
Brissart, H., Morele, E., Baumann, C., & Debouverie, M. (2012). Verbal episodic memory in 426 
multiple sclerosis patients: Impairment in encoding, retrieval or both? Neurological Sciences, 
33(5), 1117-1123. doi:10.1007/s10072-011-0915-7 
Brown, R. F., Valpiani, E. M., Tennant, C. C., Dunn, S. M., Sharrock, M., Hodgkinson, S., & Pollard, 
J. D. (2009). Longitudinal assessment of anxiety, depression, and fatigue in people with 
multiple sclerosis. Psychology and Psychotherapy, 82(Pt 1), 41-56. 
doi:10.1348/147608308X345614 
  
92 
 
Bruce-Keller, A. J., Keller, J. N., & Morrison, C. D. (2009). Obesity and vulnerability of the CNS. 
Biochimica et Biophysica Acta, 1792(5), 395-400. doi:10.1016/j.bbadis.2008.10.004 
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. 
(2004). Bariatric surgery: A systematic review and meta-analysis. JAMA, 292(14), 1724-
1737. doi:10.1001/jama.292.14.1724 
Bulik, C. M., Wade, T. D., Heath, A. C., Martin, N. G., Stunkard, A. J., & Eaves, L. J. (2001). 
Relating body mass index to figural stimuli: Population-based normative data for Caucasians. 
International Journal of Obesity and Related Metabolic Disorders, 25(10), 1517-1524. 
doi:10.1038/sj.ijo.0801742 
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight, obesity, and 
mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal 
of Medicine, 348(17), 1625-1638. doi:10.1056/NEJMoa021423 
Cambil-Martín, J., Galiano-Castillo, N., Muñoz-Hellín, E., Díaz-Rodríguez, L., Laguarta-Val, S., 
Fernández-de-Las-Peñas, C., & Arroyo-Morales, M. (2014). Influence of body mass index on 
psychological and functional outcomes in patients with multiple sclerosis: A cross-sectional 
study. Nutritional Neuroscience. doi:10.1179/1476830514Y.0000000156 
Cantorna, M. T. (2008). Vitamin D and multiple sclerosis: An update. Nutrition Reviews, 66(10 Suppl 
2), S135-138. doi:10.1111/j.1753-4887.2008.00097.x 
Carmona, R. H. (2003). The obesity crisis in America. Washington, DC. 
Carnell, S., Edwards, C., Croker, H., Boniface, D., & Wardle, J. (2005). Parental perceptions of 
overweight in 3-5 y olds. International Journal of Obesity (2005), 29(4), 353-355. 
doi:10.1038/sj.ijo.0802889 
Carr, D., & Friedman, M. A. (2005). Is obesity stigmatizing? Body weight, perceived discrimination, 
and psychological well-being in the United States. Journal of Health and Social Behavior, 
46(3), 244-259.  
Cawley, J., Rizzo, J. A., & Haas, K. (2007). Occupation-specific absenteeism costs associated with 
obesity and morbid obesity. Journal of Occupational and Environmental Medicine, 49(12), 
1317-1324. doi:10.1097/JOM.0b013e31815b56a0 
Chaboyer, W., Lee, B. O., Wallis, M., Gillespie, B., & Jones, C. (2010). Illness representations 
predict health-related quality of life 6 months after hospital discharge in individuals with 
injury: A predictive survey. Journal of Advanced Nursing, 66(12), 2743-2750. 
doi:10.1111/j.1365-2648.2010.05431.x 
Chassaing, B., & Gewirtz, A. T. (2014). Gut microbiota, low-grade inflammation, and metabolic 
syndrome. Toxicologic Pathology, 42(1), 49-53. doi:10.1177/0192623313508481 
Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. 
(2015). Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic 
syndrome. Nature, 519(7541), 92-96. doi:10.1038/nature14232 
Chaudhuri, A., & Behan, P. O. (2000). Fatigue and basal ganglia. Journal of the Neurological 
Sciences, 179(S 1-2), 34-42.  
Chiaravalloti, N. D., & DeLuca, J. (2008). Cognitive impairment in multiple sclerosis. Lancet 
Neurology, 7(12), 1139-1151. doi:10.1016/S1474-4422(08)70259-X 
Chodera, J., & Levell, R. (1973). Footprint patterns during walking. Baltimore, MD: University Park 
Press. 
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in 
adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of 
Overweight in Adults. (1998). American Journal of Clinical Nutrition, 68(4), 899-917.  
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000). Relapses and progression of 
disability in multiple sclerosis. New England Journal of Medicine, 343(20), 1430-1438. 
doi:10.1056/NEJM200011163432001 
Corboy, J. R., Goodin, D. S., & Frohman, E. M. (2003). Disease-modifying therapies for multiple 
sclerosis. Current Treatment Options in Neurology, 5(1), 35-54.  
  
93 
 
Correale, J., Ysrraelit, M. C., & Gaitán, M. I. (2009). Immunomodulatory effects of Vitamin D in 
multiple sclerosis. Brain, 132(Pt 5), 1146-1160. doi:10.1093/brain/awp033 
Corthals, A. P. (2011). Multiple sclerosis is not a disease of the immune system. Quarterly Review of 
Biology, 86(4), 287-321.  
Craddock, D., & Thomas, A. (2006). Cytokines and late-life depression. Essent Psychopharmacol, 
7(1), 42-52.  
Dalgas, U., & Stenager, E. (2012). Exercise and disease progression in multiple sclerosis: Can 
exercise slow down the progression of multiple sclerosis? Therapeutic Advances in 
Neurological Disorders, 5(2), 81-95. doi:10.1177/1756285611430719 
Dalgas, U., Stenager, E., & Ingemann-Hansen, T. (2008). Multiple sclerosis and physical exercise: 
recommendations for the application of resistance-, endurance- and combined training. 
Multiple Sclerosis, 14(1), 35-53. doi:10.1177/1352458507079445 
Dallman, M. F., Pecoraro, N. C., La Fleur, S. E., Warne, J. P., Ginsberg, A. B., Akana, S. F., . . . Bell, 
M. E. (2006). Glucocorticoids, chronic stress, and obesity. Progress in Brain Research, 153, 
75-105. doi:10.1016/S0079-6123(06)53004-3 
De Bellis, M. D., Gold, P. W., Geracioti, T. D., Listwak, S. J., & Kling, M. A. (1993). Association of 
fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing 
hormone and arginine vasopressin in patients with major depression. American Journal of 
Psychiatry, 150(4), 656-657.  
De Stefano, N., Narayanan, S., Francis, G. S., Arnaoutelis, R., Tartaglia, M. C., Antel, J. P., . . . 
Arnold, D. L. (2001). Evidence of axonal damage in the early stages of multiple sclerosis and 
its relevance to disability. Archives of Neurology, 58(1), 65-70.  
Deep, P. (1999). Biological and biopsychosocial models of health and disease in dentistry. Journal of 
the Canadian Dental Association. Journal de L'Association Dentaire Canadienne, 65(9), 
496-497.  
DeLuca, J., Barbieri-Berger, S., & Johnson, S. K. (1994). The nature of memory impairments in 
multiple sclerosis: Acquisition versus retrieval. Journal of Clinical and Experimental 
Neuropsychology, 16(2), 183-189. doi:10.1080/01688639408402629 
DeLuca, J., Chelune, G. J., Tulsky, D. S., Lengenfelder, J., & Chiaravalloti, N. D. (2004). Is speed of 
processing or working memory the primary information processing deficit in multiple 
sclerosis? Journal of Clinical and Experimental Neuropsychology, 26(4), 550-562. 
doi:10.1080/13803390490496641 
DeLuca, J., Genova, H. M., Hillary, F. G., & Wylie, G. (2008). Neural correlates of cognitive fatigue 
in multiple sclerosis using functional MRI. Journal of the Neurological Sciences, 270(1-2), 
28-39. doi:10.1016/j.jns.2008.01.018 
Demaree, H. A., DeLuca, J., Gaudino, E. A., & Diamond, B. J. (1999). Speed of information 
processing as a key deficit in multiple sclerosis: Implications for rehabilitation. Journal of 
Neurology, Neurosurgery and Psychiatry, 67(5), 661-663.  
Desvergne, B., Michalik, L., & Wahli, W. (2006). Transcriptional regulation of metabolism. 
Physiological Reviews, 86(2), 465-514. doi:10.1152/physrev.00025.2005 
Dodds, C. M., Morein-Zamir, S., & Robbins, T. W. (2011). Dissociating inhibition, attention, and 
response control in the frontoparietal network using functional magnetic resonance imaging. 
Cerebral Cortex, 21(5), 1155-1165. doi:10.1093/cercor/bhq187 
du Boisgueheneuc, F., Levy, R., Volle, E., Seassau, M., Duffau, H., Kinkingnehun, S., . . . Dubois, B. 
(2006). Functions of the left superior frontal gyrus in humans: A lesion study. Brain, 129(Pt 
12), 3315-3328. doi:10.1093/brain/awl244 
Duclos, M., Gatta, B., Corcuff, J. B., Rashedi, M., Pehourcq, F., & Roger, P. (2001). Fat distribution 
in obese women is associated with subtle alterations of the hypothalamic-pituitary-adrenal 
axis activity and sensitivity to glucocorticoids. Clinical Endocrinology, 55(4), 447-454.  
  
94 
 
Dunn, J. (2010). Impact of mobility impairment on the burden of caregiving in individuals with 
multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 433-
440. doi:10.1586/erp.10.34 
Dyrstad, S. M., Hansen, B. H., Holme, I. M., & Anderssen, S. A. (2014). Comparison of self-reported 
versus accelerometer-measured physical activity. Medicine and Science in Sports and 
Exercise, 46(1), 99-106. doi:10.1249/MSS.0b013e3182a0595f 
Elias, M. F., Elias, P. K., Sullivan, L. M., Wolf, P. A., & D'Agostino, R. B. (2003). Lower cognitive 
function in the presence of obesity and hypertension: The Framingham heart study. 
International Journal of Obesity and Related Metabolic Disorders, 27(2), 260-268. 
doi:10.1038/sj.ijo.802225 
Elias, M. F., Elias, P. K., Sullivan, L. M., Wolf, P. A., & D'Agostino, R. B. (2005). Obesity, diabetes 
and cognitive deficit: The Framingham Heart Study. Neurobiology of Aging, 26 Suppl 1, 11-
16. doi:10.1016/j.neurobiolaging.2005.08.019 
Elmquist, J. K., Bjørbaek, C., Ahima, R. S., Flier, J. S., & Saper, C. B. (1998). Distributions of leptin 
receptor mRNA isoforms in the rat brain. Journal of Comparative Neurology, 395(4), 535-
547.  
Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 
196(4286), 129-136.  
Engel, G. L. (2012). The need for a new medical model: A challenge for biomedicine. Psychodyn 
Psychiatry, 40(3), 377-396. doi:10.1521/pdps.2012.40.3.377 
Etelson, D., Brand, D. A., Patrick, P. A., & Shirali, A. (2003). Childhood obesity: Do parents 
recognize this health risk? Obesity Research, 11(11), 1362-1368. doi:10.1038/oby.2003.184 
Ettinger, W. H., Fried, L. P., Harris, T., Shemanski, L., Schulz, R., & Robbins, J. (1994). Self-
reported causes of physical disability in older people: The Cardiovascular Health Study. CHS 
Collaborative Research Group. Journal of the American Geriatrics Society, 42(10), 1035-
1044.  
Farr, S. A., Yamada, K. A., Butterfield, D. A., Abdul, H. M., Xu, L., Miller, N. E., . . . Morley, J. E. 
(2008). Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology, 
149(5), 2628-2636. doi:10.1210/en.2007-1722 
Fassbender, K., Schmidt, R., Mössner, R., Kischka, U., Kühnen, J., Schwartz, A., & Hennerici, M. 
(1998). Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in 
multiple sclerosis: Association with cerebral inflammation. Archives of Neurology, 55(1), 66-
72.  
Fei, H., Okano, H. J., Li, C., Lee, G. H., Zhao, C., Darnell, R., & Friedman, J. M. (1997). Anatomic 
localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. 
Proceedings of the National Academy of Sciences of the United States of America, 94(13), 
7001-7005.  
Feinstein, A., Magalhaes, S., Richard, J. F., Audet, B., & Moore, C. (2014). The link between 
multiple sclerosis and depression. Nature Reviews: Neurology, 10(9), 507-517. 
doi:10.1038/nrneurol.2014.139 
Feinstein, A., O'Connor, P., Gray, T., & Feinstein, K. (1999). The effects of anxiety on psychiatric 
morbidity in patients with multiple sclerosis. Multiple Sclerosis, 5(5), 323-326.  
Feinstein, A., Roy, P., Lobaugh, N., Feinstein, K., O'Connor, P., & Black, S. (2004). Structural brain 
abnormalities in multiple sclerosis patients with major depression. Neurology, 62(4), 586-
590.  
Filippi, M., Rocca, M. A., Colombo, B., Falini, A., Codella, M., Scotti, G., & Comi, G. (2002). 
Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. 
Neuroimage, 15(3), 559-567. doi:10.1006/nimg.2001.1011 
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009). Annual medical spending 
attributable to obesity: Payer-and service-specific estimates. Health Affairs, 28(5), w822-831. 
doi:10.1377/hlthaff.28.5.w822 
  
95 
 
Fischer, J. S., Rudick, R. A., Cutter, G. R., & Reingold, S. C. (1999). The Multiple Sclerosis 
Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome 
assessment. National MS Society Clinical Outcomes Assessment Task Force. Multiple 
Sclerosis, 5(4), 244-250.  
Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of 
fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9-
14.  
Fleary, S., & Ettiene, R. (2014). Inherited or behavior? What causal beliefs about obesity are 
associated with weight perceptions and decisions to lose weight in a US sample? 
International Scholarly Research Notices. doi:10.1155/2014/632940 
Foong, J., Rozewicz, L., Davie, C. A., Thompson, A. J., Miller, D. H., & Ron, M. A. (1999). 
Correlates of executive function in multiple sclerosis: The use of magnetic resonance 
spectroscopy as an index of focal pathology. Journal of Neuropsychiatry and Clinical 
Neurosciences, 11(1), 45-50.  
Foong, J., Rozewicz, L., Quaghebeur, G., Davie, C. A., Kartsounis, L. D., Thompson, A. J., . . . Ron, 
M. A. (1997). Executive function in multiple sclerosis. The role of frontal lobe pathology. 
Brain, 120 ( Pt 1), 15-26.  
Friedman, M. A., & Brownell, K. D. (1995). Psychological correlates of obesity: Moving to the next 
research generation. Psychological Bulletin, 117(1), 3-20.  
Fulcher, K. Y., & White, P. D. (1997). Randomised controlled trial of graded exercise in patients with 
the chronic fatigue syndrome. BMJ, 314(7095), 1647-1652.  
Fultz, N. H., Ofstedal, M. B., Herzog, A. R., & Wallace, R. B. (2003). Additive and interactive effects 
of comorbid physical and mental conditions on functional health. Journal of Aging and 
Health, 15(3), 465-481. doi:10.1177/0898264303253502 
Gariepy, G., Nitka, D., & Schmitz, M. (2010). The association between obesity and anxiety disorders 
in the population: A systematic review and meta-analysis. International Journal of Obesity, 
34, 407-419.  
Geffen, G. M., Butterworth, P., & Geffen, L. B. (1994). Test-retest reliability of a new form of the 
auditory verbal learning test (AVLT). Archives of Clinical Neuropsychology, 9(4), 303-316.  
Gillum, R. F., & Sempos, C. T. (2005). Ethnic variation in validity of classification of overweight and 
obesity using self-reported weight and height in American women and men: The Third 
National Health and Nutrition Examination Survey. Nutrition Journal, 4, 27. 
doi:10.1186/1475-2891-4-27 
Glenny, A. M., O'Meara, S., Melville, A., Sheldon, T. A., & Wilson, C. (1997). The treatment and 
prevention of obesity: A systematic review of the literature. International Journal of Obesity 
and Related Metabolic Disorders, 21(9), 715-737.  
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., . . . 
Subcommittee, A. H. A. S. C. a. S. S. (2014). Heart disease and stroke statistics-2014 update: 
A report from the American Heart Association. Circulation, 129(3), e28-e292. 
doi:10.1161/01.cir.0000441139.02102.80 
Gold, S. M., & Irwin, M. R. (2009). Depression and immunity: Inflammation and depressive 
symptoms in multiple sclerosis. Immunology and Allergy Clinics of North America, 29(2), 
309-320. doi:10.1016/j.iac.2009.02.008 
Gomersall, S. R., Norton, K., Maher, C., English, C., & Olds, T. S. (2015). In search of lost time: 
When people undertake a new exercise program, where does the time come from? A 
randomized controlled trial. Journal of Science and Medicine in Sport, 18(1), 43-48. 
doi:10.1016/j.jsams.2014.01.004 
Gottschalk, M., Kümpfel, T., Flachenecker, P., Uhr, M., Trenkwalder, C., Holsboer, F., & Weber, F. 
(2005). Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. 
Archives of Neurology, 62(2), 277-280. doi:10.1001/archneur.62.2.277 
Greeno, C. G., & Wing, R. R. (1994). Stress-induced eating. Psychological Bulletin, 115(3), 444-464.  
  
96 
 
Gregg, E. W., Beckles, G. L., Williamson, D. F., Leveille, S. G., Langlois, J. A., Engelgau, M. M., & 
Narayan, K. M. (2000). Diabetes and physical disability among older U.S. adults. Diabetes 
Care, 23(9), 1272-1277.  
Gromisch, E. S., Zemon, V., Holtzer, R., Chiaravalloti, N. D., DeLuca, J., Beier, M., . . . Foley, F. W. 
(2016). Assessing the criterion validity of four highly abbreviated measures from the Minimal 
Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). Clinical 
Neuropsychologist, 30(7), 1032-1049. doi:10.1080/13854046.2016.1189597 
Gunstad, J., Paul, R. H., Cohen, R. A., Tate, D. F., Spitznagel, M. B., & Gordon, E. (2007). Elevated 
body mass index is associated with executive dysfunction in otherwise healthy adults. 
Comprehensive Psychiatry, 48(1), 57-61. doi:10.1016/j.comppsych.2006.05.001 
Hampshire, A., Chamberlain, S. R., Monti, M. M., Duncan, J., & Owen, A. M. (2010). The role of the 
right inferior frontal gyrus: Inhibition and attentional control. Neuroimage, 50(3), 1313-1319. 
doi:10.1016/j.neuroimage.2009.12.109 
Hara, M., Saitou, E., Iwata, F., Okada, T., & Harada, K. (2002). Waist-to-height ratio is the best 
predictor of cardiovascular disease risk factors in Japanese schoolchildren. J Atheroscler 
Thromb, 9(3), 127-132.  
Harvey, J. (2007). Leptin regulation of neuronal excitability and cognitive function. Current Opinion 
in Pharmacology, 7(6), 643-647. doi:10.1016/j.coph.2007.10.006 
Hayes, C. E., Cantorna, M. T., & DeLuca, H. F. (1997). Vitamin D and multiple sclerosis. 
Proceedings of the Society for Experimental Biology and Medicine, 216(1), 21-27.  
Haynes, R. B., McDonald, H. P., & Garg, A. X. (2002). Helping patients follow prescribed treatment: 
Clinical applications. JAMA, 288(22), 2880-2883.  
Hedström, A. K., Olsson, T., & Alfredsson, L. (2012). High body mass index before age 20 is 
associated with increased risk for multiple sclerosis in both men and women. Multiple 
Sclerosis, 18(9), 1334-1336. doi:10.1177/1352458512436596 
Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the 
impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 
60(1), 31-36.  
Induruwa, I., Constantinescu, C. S., & Gran, B. (2012). Fatigue in multiple sclerosis - a brief review. 
Journal of the Neurological Sciences, 323(1-2), 9-15. doi:10.1016/j.jns.2012.08.007 
Irani, J., & Abell, R. (2007). Awareness of body weight status among family medicine clinic patients. 
Journal - Oklahoma State Medical Association, 100(5), 139-143.  
Jadelis, K., Miller, M. E., Ettinger, W. H., & Messier, S. P. (2001). Strength, balance, and the 
modifying effects of obesity and knee pain: Results from the Observational Arthritis Study in 
Seniors (oasis). Journal of the American Geriatrics Society, 49(7), 884-891.  
Johnson-Taylor, W. L., Fisher, R. A., Hubbard, V. S., Starke-Reed, P., & Eggers, P. S. (2008). The 
change in weight perception of weight status among the overweight: Comparison of 
NHANES III (1988-1994) and 1999-2004 NHANES. The International Journal of 
Behavioral Nutrition and Physical Activity, 5, 9. doi:10.1186/1479-5868-5-9 
Jones, K. H., Ford, D. V., Jones, P. A., John, A., Middleton, R. M., Lockhart-Jones, H., . . . Noble, J. 
G. (2012). A large-scale study of anxiety and depression in people with multiple sclerosis: A 
survey via the web portal of the UK MS Register. PloS One, 7(7), e41910. 
doi:10.1371/journal.pone.0041910 
Jopson, N. M., & Moss-Morris, R. (2003). The role of illness severity and illness representations in 
adjusting to multiple sclerosis. Journal of Psychosomatic Research, 54(6), 503-511; 
discussion 513-504.  
Judd, L. L., Akiskal, H. S., Zeller, P. J., Paulus, M., Leon, A. C., Maser, J. D., . . . Keller, M. B. 
(2000). Psychosocial disability during the long-term course of unipolar major depressive 
disorder. Archives of General Psychiatry, 57(4), 375-380.  
Kanaya, A. M., Barrett-Connor, E., Gildengorin, G., & Yaffe, K. (2004). Change in cognitive 
function by glucose tolerance status in older adults: A 4-year prospective study of the Rancho 
  
97 
 
Bernardo study cohort. Archives of Internal Medicine, 164(12), 1327-1333. 
doi:10.1001/archinte.164.12.1327 
Kappus, N., Weinstock-Guttman, B., Hagemeier, J., Kennedy, C., Melia, R., Carl, E., . . . Zivadinov, 
R. (2015). Cardiovascular risk factors are associated with increased lesion burden and brain 
atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 
doi:10.1136/jnnp-2014-310051 
Kejonen, P., Kauranen, K., & Vanharanta, H. (2003). The relationship between anthropometric 
factors and body-balancing movements in postural balance. Archives of Physical Medicine 
and Rehabilitation, 84(1), 17-22. doi:10.1053/apmr.2003.50058 
Kenis, G., & Maes, M. (2002). Effects of antidepressants on the production of cytokines. 
International Journal of Neuropsychopharmacology, 5(4), 401-412. 
doi:10.1017/S1461145702003164 
Kern, S., Schultheiss, T., Schneider, H., Schrempf, W., Reichmann, H., & Ziemssen, T. (2011). 
Circadian cortisol, depressive symptoms and neurological impairment in early multiple 
sclerosis. Psychoneuroendocrinology, 36(10), 1505-1512. 
doi:10.1016/j.psyneuen.2011.04.004 
Kim, Y. K., Na, K. S., Shin, K. H., Jung, H. Y., Choi, S. H., & Kim, J. B. (2007). Cytokine imbalance 
in the pathophysiology of major depressive disorder. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 31(5), 1044-1053. 
doi:10.1016/j.pnpbp.2007.03.004 
Klerman, G. L. (1989). Depressive disorders: Further evidence for increased medical morbidity and 
impairment of social functioning. Archives of General Psychiatry, 46(9), 856-858.  
Klerman, G. L., & Weissman, M. M. (1992). The course, morbidity, and costs of depression. Archives 
of General Psychiatry, 49(10), 831-834.  
Kolotkin, R. L., Meter, K., & Williams, G. R. (2001). Quality of life and obesity. Obesity Reviews, 
2(4), 219-229.  
Kopelman, P. (2007). Health risks associated with overweight and obesity. Obesity Reviews, 8 Suppl 
1, 13-17. doi:10.1111/j.1467-789X.2007.00311.x 
Kos, D., Kerckhofs, E., Nagels, G., D'hooghe, M. B., & Ilsbroukx, S. (2008). Origin of fatigue in 
multiple sclerosis: Review of the literature. Neurorehabilitation and Neural Repair, 22(1), 
91-100. doi:10.1177/1545968306298934 
Kroencke, D. C., Lynch, S. G., & Denney, D. R. (2000). Fatigue in multiple sclerosis: Relationship to 
depression, disability, and disease pattern. Multiple Sclerosis, 6(2), 131-136. 
doi:10.1177/135245850000600213 
Kubera, M., Maes, M., Kenis, G., Kim, Y. K., & Lasoń, W. (2005). Effects of serotonin and 
serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and 
interleukin-6. Psychiatry Research, 134(3), 251-258. doi:10.1016/j.psychres.2004.01.014 
Kuo, H. K., Jones, R. N., Milberg, W. P., Tennstedt, S., Talbot, L., Morris, J. N., & Lipsitz, L. A. 
(2006). Cognitive function in normal-weight, overweight, and obese older adults: An analysis 
of the Advanced Cognitive Training for Independent and Vital Elderly cohort. Journal of the 
American Geriatrics Society, 54(1), 97-103. doi:10.1111/j.1532-5415.2005.00522.x 
Langer-Gould, A., Brara, S. M., Beaber, B. E., & Koebnick, C. (2013). Childhood obesity and risk of 
pediatric multiple sclerosis and clinically isolated syndrome. Neurology, 80(6), 548-552. 
doi:10.1212/WNL.0b013e31828154f3 
Latimer-Cheung, A. E., Martin Ginis, K. A., Hicks, A. L., Motl, R. W., Pilutti, L. A., Duggan, M., . . . 
Smith, K. M. (2013). Development of evidence-informed physical activity guidelines for 
adults with multiple sclerosis. Archives of Physical Medicine and Rehabilitation, 94(9), 1829-
1836.e1827. doi:10.1016/j.apmr.2013.05.015 
Latimer-Cheung, A. E., Pilutti, L. A., Hicks, A. L., Martin Ginis, K. A., Fenuta, A. M., MacKibbon, 
K. A., & Motl, R. W. (2013). Effects of exercise training on fitness, mobility, fatigue, and 
health-related quality of life among adults with multiple sclerosis: A systematic review to 
  
98 
 
inform guideline development. Archives of Physical Medicine and Rehabilitation, 94(9), 
1800-1828.e1803. doi:10.1016/j.apmr.2013.04.020 
Lee, C. M., Huxley, R. R., Wildman, R. P., & Woodward, M. (2008). Indices of abdominal obesity 
are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. Journal of 
Clinical Epidemiology, 61(7), 646-653. doi:10.1016/j.jclinepi.2007.08.012 
Lee, Y. K., Menezes, J. S., Umesaki, Y., & Mazmanian, S. K. (2011). Proinflammatory T-cell 
responses to gut microbiota promote experimental autoimmune encephalomyelitis. 
Proceedings of the National Academy of Sciences of the United States of America, 108 Suppl 
1, 4615-4622. doi:10.1073/pnas.1000082107 
Lezak, M. (1995). Neuropsychological assessment, third edition (3rd ed.). In. New York: Oxford 
University Press. 
Lupien, S. J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N. P., . . . Meaney, M. J. 
(1998). Cortisol levels during human aging predict hippocampal atrophy and memory 
deficits. Nature Neuroscience, 1(1), 69-73. doi:10.1038/271 
Lupien, S. J., Nair, N. P., Brière, S., Maheu, F., Tu, M. T., Lemay, M., . . . Meaney, M. J. (1999). 
Increased cortisol levels and impaired cognition in human aging: Implication for depression 
and dementia in later life. Reviews in the Neurosciences, 10(2), 117-139.  
Lurie, A. (2011). Obstructive sleep apnea in adults: Epidemiology, clinical presentation, and 
treatment options. Advances in Cardiology, 46, 1-42. doi:10.1159/000327660 
Ma, D., Lu, L., Boneva, N. B., Warashina, S., Kaplamadzhiev, D. B., Mori, Y., . . . Yamashima, T. 
(2008). Expression of free fatty acid receptor GPR40 in the neurogenic niche of adult monkey 
hippocampus. Hippocampus, 18(3), 326-333. doi:10.1002/hipo.20393 
MacLaughlin, H. L., Cook, S. A., Kariyawasam, D., Roseke, M., van Niekerk, M., & Macdougall, I. 
C. (2010). Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and 
exercise in obese patients with CKD: 2-year follow-up. American Journal of Kidney 
Diseases, 55(1), 69-76. doi:10.1053/j.ajkd.2009.09.011 
Marcora, S. M., Staiano, W., & Manning, V. (2009). Mental fatigue impairs physical performance in 
humans. J Appl Physiol (1985), 106(3), 857-864. doi:10.1152/japplphysiol.91324.2008 
Mårin, P., Darin, N., Amemiya, T., Andersson, B., Jern, S., & Björntorp, P. (1992). Cortisol secretion 
in relation to body fat distribution in obese premenopausal women. Metabolism: Clinical and 
Experimental, 41(8), 882-886.  
Markowitz, S., Friedman, M., & Arent, S. (2008). Understanding the relation between obesity and 
depression: Causal mechanisms and implications for treatment. American Psychological 
Association, 15(1).  
Marrie, R., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D., & Vollmer, T. (2009). High frequency 
of adverse health behaviors in multiple sclerosis. Multiple Sclerosis, 15(1), 105-113. 
doi:10.1177/1352458508096680 
Marrie, R. A., Reider, N., Cohen, J., Stuve, O., Trojano, M., Cutter, G., . . . Sorensen, P. S. (2015). A 
systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral 
vascular disease in multiple sclerosis. Multiple Sclerosis, 21(3), 318-331. 
doi:10.1177/1352458514564485 
Marrie, R. A., Rudick, R., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D., & Vollmer, T. (2010). 
Vascular comorbidity is associated with more rapid disability progression in multiple 
sclerosis. Neurology, 74(13), 1041-1047. doi:10.1212/WNL.0b013e3181d6b125 
Martin, C. L., Phillips, B. A., Kilpatrick, T. J., Butzkueven, H., Tubridy, N., McDonald, E., & Galea, 
M. P. (2006). Gait and balance impairment in early multiple sclerosis in the absence of 
clinical disability. Multiple Sclerosis, 12(5), 620-628.  
Matarese, G., Carrieri, P. B., Montella, S., De Rosa, V., & La Cava, A. (2010). Leptin as a metabolic 
link to multiple sclerosis. Nature Reviews: Neurology, 6(8), 455-461. 
doi:10.1038/nrneurol.2010.89 
  
99 
 
Matarese, G., Procaccini, C., & De Rosa, V. (2008). The intricate interface between immune and 
metabolic regulation: A role for leptin in the pathogenesis of multiple sclerosis? Journal of 
Leukocyte Biology, 84(4), 893-899. doi:10.1189/jlb.0108022 
McCullagh, R., Fitzgerald, A. P., Murphy, R. P., & Cooke, G. (2008). Long-term benefits of 
exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: A 
pilot study. Clinical Rehabilitation, 22(3), 206-214. doi:10.1177/0269215507082283 
McDonald, J., Graves, J., Waldman, A., Lotze, T., Schreiner, T., Belman, A., . . . Waubant, E. (2016). 
A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Mult Scler 
Relat Disord, 6, 87-92. doi:10.1016/j.msard.2016.02.011 
McFarlin, D. E., & McFarland, H. F. (1982a). Multiple sclerosis (first of two parts). New England 
Journal of Medicine, 307(19), 1183-1188. doi:10.1056/NEJM198211043071905 
McFarlin, D. E., & McFarland, H. F. (1982b). Multiple sclerosis (second of two parts). New England 
Journal of Medicine, 307(20), 1246-1251. doi:10.1056/NEJM198211113072005 
Messer, A. E. (2012). Americans fall short of federal exercise recommendations. Penn State News. 
Retrieved from  
Messier, S. P. (2008). Obesity and osteoarthritis: disease genesis and nonpharmacologic weight 
management. Rheumatic Diseases Clinics of North America, 34(3), 713-729. 
doi:10.1016/j.rdc.2008.04.007 
Messier, S. P., Davies, A. B., Moore, D. T., Davis, S. E., Pack, R. J., & Kazmar, S. C. (1994). Severe 
obesity: Effects on foot mechanics during walking. Foot and Ankle International, 15(1), 29-
34.  
Miller, D. H., & Leary, S. M. (2007). Primary-progressive multiple sclerosis. Lancet Neurology, 
6(10), 903-912. doi:10.1016/S1474-4422(07)70243-0 
Miyatake, N., Fujii, M., Nishikawa, H., Wada, J., Shikata, K., Makino, H., & Kimura, I. (2000). 
Clinical evaluation of muscle strength in 20-79-years-old obese Japanese. Diabetes Research 
and Clinical Practice, 48(1), 15-21.  
Morley, J. E. (2004). The metabolic syndrome and aging. Journals of Gerontology. Series A: 
Biological Sciences and Medical Sciences, 59(2), 139-142.  
Motl, R. W. (2014). Benefits, safety, and prescription of exercise in persons with multiple sclerosis. 
Expert Review of Neurotherapeutics, 14(12), 1429-1436. doi:10.1586/14737175.2014.983904 
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., . . . 
Subcommittee, A. H. A. S. C. a. S. S. (2015). Heart disease and stroke statistics-2015 update: 
A report from the American Heart Association. Circulation, 131(4), e29-322. 
doi:10.1161/CIR.0000000000000152 
Munger, K. L., Bentzen, J., Laursen, B., Stenager, E., Koch-Henriksen, N., Sørensen, T. I., & Baker, 
J. L. (2013). Childhood body mass index and multiple sclerosis risk: A long-term cohort 
study. Multiple Sclerosis, 19(10), 1323-1329. doi:10.1177/1352458513483889 
Munger, K. L., Chitnis, T., & Ascherio, A. (2009). Body size and risk of MS in two cohorts of US 
women. Neurology, 73(19), 1543-1550. doi:10.1212/WNL.0b013e3181c0d6e0 
Najafi, B., Bharara, M., Talal, K., & Armstrong, D. G. (2012). Advances in balance assessment and 
balance training for diabetes. Diabetes Management, 2(4), 293-308.  
Nicklas, B. J., You, T., & Pahor, M. (2005). Behavioural treatments for chronic systemic 
inflammation: Effects of dietary weight loss and exercise training. CMAJ: Canadian Medical 
Association Journal, 172(9), 1199-1209. doi:10.1503/cmaj.1040769 
Norcini Pala, A., & Steca, P. (2015). Illness perceptions and coping strategies among individuals 
diagnosed with HIV. Journal of Behavioral Medicine. doi:10.1007/s10865-015-9639-0 
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. (2000). World 
Health Organization Technical Report Series, 894, i-xii, 1-253.  
Onyike, C. U., Crum, R. M., Lee, H. B., Lyketsos, C. G., & Eaton, W. W. (2003). Is obesity 
associated with major depression? Results from the Third National Health and Nutrition 
Examination Survey. American Journal of Epidemiology, 158(12), 1139-1147.  
  
100 
 
Padgett, P. K., & Kasser, S. L. (2013). Exercise for managing the symptoms of multiple sclerosis. 
Physical Therapy, 93(6), 723-728. doi:10.2522/ptj.20120178 
Paeratakul, S., White, M. A., Williamson, D. A., Ryan, D. H., & Bray, G. A. (2002). Sex, 
race/ethnicity, socioeconomic status, and BMI in relation to self-perception of overweight. 
Obesity Research, 10(5), 345-350. doi:10.1038/oby.2002.48 
Pakpoor, J., Seminatore, B., Graves, J., Schreiner, T., Waldman, A., Lotze, T., . . . Waubant, E. 
(2016). Dietary factors and risk of pediatric multiple sclerosis. Neurology, 86(16; 
Supplement      S29.006).  
Pannacciulli, N., Del Parigi, A., Chen, K., Le, D. S., Reiman, E. M., & Tataranni, P. A. (2006). Brain 
abnormalities in human obesity: A voxel-based morphometric study. Neuroimage, 31(4), 
1419-1425. doi:10.1016/j.neuroimage.2006.01.047 
Parmenter, B. A., Weinstock-Guttman, B., Garg, N., Munschauer, F., & Benedict, R. H. (2007). 
Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities 
Test. Multiple Sclerosis, 13(1), 52-57.  
Parrott, M. D., & Greenwood, C. E. (2007). Dietary influences on cognitive function with aging: 
From high-fat diets to healthful eating. Annals of the New York Academy of Sciences, 1114, 
389-397. doi:10.1196/annals.1396.028 
Pasquali, R., Cantobelli, S., Casimirri, F., Capelli, M., Bortoluzzi, L., Flamia, R., . . . Barbara, L. 
(1993). The hypothalamic-pituitary-adrenal axis in obese women with different patterns of 
body fat distribution. Journal of Clinical Endocrinology and Metabolism, 77(2), 341-346. 
doi:10.1210/jcem.77.2.8393881 
Patil, S., & Chan, C. (2005). Palmitic and stearic fatty acids induce Alzheimer-like 
hyperphosphorylation of tau in primary rat cortical neurons. Neuroscience Letters, 384(3), 
288-293. doi:10.1016/j.neulet.2005.05.003 
Patterson, J. A., Amick, R. Z., Pandya, P. D., Hakansson, N., & Jorgensen, M. J. (2014). Comparison 
of a mobile technology application with the balance error scoring system. International 
Journal of Athletic Therapy and Training, 19(3), 4-7. doi:10.1123/ijatt.2013-0094 
Patterson, J. A., Amick, R. Z., Thummar, T., & Rogers, M. E. (2014). Validation of measures from 
the smartphone sway balance application: A pilot study. International Journal of Sports 
Physical Therapy, 9(2), 135-139.  
Paul, R. H., Beatty, W. W., Schneider, R., Blanco, C., & Hames, K. (1998). Impairments of attention 
in individuals with multiple sclerosis. Multiple Sclerosis, 4(5), 433-439.  
Pellicano, C., Gallo, A., Li, X., Ikonomidou, V. N., Evangelou, I. E., Ohayon, J. M., . . . Bagnato, F. 
(2010). Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Archives 
of Neurology, 67(4), 447-453. doi:10.1001/archneurol.2010.48 
Peng, Y. G., Li, Y., Guo, M., Tian, Y., Li, X., Li, S. H., . . . Zhao, L. C. (2013). The optimal cut-off 
value of waist-to-height ratio for detecting severe central obesity and low body weight adult 
Chinese population. Zhonghua Xin Xue Guan Bing Za Zhi, 41(7), 607-610.  
Pérusse, L., Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., . . . 
Bouchard, C. (2005). The human obesity gene map: The 2004 update. Obesity Research, 
13(3), 381-490. doi:10.1038/oby.2005.50 
Pilutti, L. A., Dlugonski, D., Pula, J. H., & Motl, R. W. (2012). Weight status in persons with 
multiple sclerosis: Implications for mobility outcomes. Journal of Obesity, 2012, 868256. 
doi:10.1155/2012/868256 
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., . . . Wolinsky, J. S. 
(2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. 
Annals of Neurology, 69(2), 292-302. doi:10.1002/ana.22366 
Puhl, R., & Brownell, K. D. (2003). Ways of coping with obesity stigma: Review and conceptual 
analysis. Eat Behav, 4(1), 53-78.  
  
101 
 
Quiles Marcos, Y., Terol Cantero, M. C., Romero Escobar, C., & Pagán Acosta, G. (2007). Illness 
perception in eating disorders and psychosocial adaptation. Eur Eat Disord Rev, 15(5), 373-
384. doi:10.1002/erv.793 
Ramagopalan, S. V., Byrnes, J. K., Orton, S. M., Dyment, D. A., Guimond, C., Yee, I. M., . . . 
Sadovnick, A. D. (2010). Sex ratio of multiple sclerosis and clinical phenotype. European 
Journal of Neurology, 17(4), 634-637. doi:10.1111/j.1468-1331.2009.02850.x 
Resnick, H. E., Carter, E. A., Aloia, M., & Phillips, B. (2006). Cross-sectional relationship of 
reported fatigue to obesity, diet, and physical activity: Results from the third national health 
and nutrition examination survey. Journal of Clinical Sleep Medicine, 2(2), 163-169.  
Riccio, P., & Rossano, R. (2015). Nutrition facts in multiple sclerosis. ASN Neuro, 7(1). 
doi:10.1177/1759091414568185 
Riccitelli, G., Rocca, M. A., Pagani, E., Rodegher, M. E., Rossi, P., Falini, A., . . . Filippi, M. (2011). 
Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter 
atrophy according to clinical phenotype. Human Brain Mapping, 32(10), 1535-1543. 
doi:10.1002/hbm.21125 
Riddle, D. L., Pulisic, M., Pidcoe, P., & Johnson, R. E. (2003). Risk factors for plantar fasciitis: A 
matched case-control study. Journal of Bone and Joint Surgery (American Volume), 85-A(5), 
872-877.  
Ritvo, P. (1997). MSQLI Multiple Sclerosis Quality of Life Inventory: A user's manusal. In t. C. o. 
M. S. c. H. S. R. Subcommittee (Ed.). New York, NY: National Multiple Sclerosis Society. 
Rizzo, M. A., Hadjimichael, O. C., Preiningerova, J., & Vollmer, T. L. (2004). Prevalence and 
treatment of spasticity reported by multiple sclerosis patients. Multiple Sclerosis, 10(5), 589-
595.  
Roberts, R. E., Deleger, S., Strawbridge, W. J., & Kaplan, G. A. (2003). Prospective association 
between obesity and depression: Evidence from the Alameda County Study. International 
Journal of Obesity and Related Metabolic Disorders, 27(4), 514-521. 
doi:10.1038/sj.ijo.0802204 
Roberts, R. E., Kaplan, G. A., Shema, S. J., & Strawbridge, W. J. (2000). Are the obese at greater risk 
for depression? American Journal of Epidemiology, 152(2), 163-170.  
Rodea-Montero, E. R., Evia-Viscarra, M. L., & Apolinar-Jiménez, E. (2014). Waist-to-height ratio is 
a better anthropometric index than waist circumference and BMI in predicting metabolic 
syndrome among obese Mexican adolescents. International Journal of Endocrinology, 2014, 
195407. doi:10.1155/2014/195407 
Romero-Corral, A., Caples, S. M., Lopez-Jimenez, F., & Somers, V. K. (2010). Interactions between 
obesity and obstructive sleep apnea: Implications for treatment. Chest, 137(3), 711-719. 
doi:10.1378/chest.09-0360 
Ron, M. A., & Logsdail, S. J. (1989). Psychiatric morbidity in multiple sclerosis: A clinical and MRI 
study. Psychological Medicine, 19(4), 887-895.  
Rozema, H., Völlink, T., & Lechner, L. (2009). The role of illness representations in coping and 
health of patients treated for breast cancer. Psycho-Oncology, 18(8), 849-857. 
doi:10.1002/pon.1488 
Rubenstein, L. Z. (2006). Falls in older people: Epidemiology, risk factors and strategies for 
prevention. Age and Ageing, 35 Suppl 2, ii37-ii41. doi:10.1093/ageing/afl084 
Ruff, R. M., Light, R. H., Parker, S. B., & Levin, H. S. (1996). Benton Controlled Oral Word 
Association Test: Reliability and updated norms. Archives of Clinical Neuropsychology, 
11(4), 329-338.  
Ryan, J. J., & Geisser, M. E. (1986). Validity and diagnostic accuracy of an alternate form of the Rey 
Auditory Verbal Learning Test. Archives of Clinical Neuropsychology, 1(3), 209-217.  
Ryerson, B., Tierney, E. F., Thompson, T. J., Engelgau, M. M., Wang, J., Gregg, E. W., & Geiss, L. 
S. (2003). Excess physical limitations among adults with diabetes in the U.S. population, 
1997-1999. Diabetes Care, 26(1), 206-210.  
  
102 
 
Sadovnick, A. D., Eisen, K., Ebers, G. C., & Paty, D. W. (1991). Cause of death in patients attending 
multiple sclerosis clinics. Neurology, 41(8), 1193-1196.  
Shamseddeen, H., Getty, J. Z., Hamdallah, I. N., & Ali, M. R. (2011). Epidemiology and economic 
impact of obesity and type 2 diabetes. Surgical Clinics of North America, 91(6), 1163-1172, 
vii. doi:10.1016/j.suc.2011.08.001 
Sharifi, N., Mahdavi, R., & Ebrahimi-Mameghani, M. (2013). Perceived barriers to weight loss 
programs for overweight or obese women. Health Promot Perspect, 3(1), 11-22. 
doi:10.5681/hpp.2013.002 
Siegert, R. J., & Abernethy, D. A. (2005). Depression in multiple sclerosis: A review. Journal of 
Neurology, Neurosurgery and Psychiatry, 76(4), 469-475. doi:10.1136/jnnp.2004.054635 
Slawta, J. N., Wilcox, A. R., McCubbin, J. A., Nalle, D. J., Fox, S. D., & Anderson, G. (2003). Health 
behaviors, body composition, and coronary heart disease risk in women with multiple 
sclerosis. Archives of Physical Medicine and Rehabilitation, 84(12), 1823-1830.  
Smith, A. (1982). Symbol Digit Modalities Test (SDMT) Manual (Revised). In. Los Angeles: 
Western Psychological Services. 
Solari, A., Filippini, G., Gasco, P., Colla, L., Salmaggi, A., La Mantia, L., . . . Mendozzi, L. (1999). 
Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. 
Neurology, 52(1), 57-62.  
Sospedra, M., & Martin, R. (2005). Immunology of multiple sclerosis. Annual Review of 
Immunology, 23, 683-747. doi:10.1146/annurev.immunol.23.021704.115707 
Sotgiu, S., Angius, A., Embry, A., Rosati, G., & Musumeci, S. (2008). Hygiene hypothesis: Innate 
immunity, malaria and multiple sclerosis. Medical Hypotheses, 70(4), 819-825. 
doi:10.1016/j.mehy.2006.10.069 
Steinman, L. (2009). A molecular trio in relapse and remission in multiple sclerosis. Nature Reviews: 
Immunology, 9(6), 440-447. doi:10.1038/nri2548 
Stenager, E. N., Stenager, E., Koch-Henriksen, N., Brønnum-Hansen, H., Hyllested, K., Jensen, K., & 
Bille-Brahe, U. (1992). Suicide and multiple sclerosis: An epidemiological investigation. 
Journal of Neurology, Neurosurgery and Psychiatry, 55(7), 542-545.  
Steultjens, E. M., Dekker, J., Bouter, L. M., Cardol, M., Van de Nes, J. C., & Van den Ende, C. H. 
(2003). Occupational therapy for multiple sclerosis. Cochrane Database Syst Rev(3), 
CD003608. doi:10.1002/14651858.CD003608 
Stotland, S., & Zuroff, D. C. (1990). A new measure of weight locus of control: The Dieting Beliefs 
Scale. Journal of Personality Assessment, 54(1-2), 191-203. 
doi:10.1080/00223891.1990.9673986 
Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K., Egan, J. M., & Mattson, M. P. (2008). 
Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and 
mature neurons. Nature Neuroscience, 11(3), 309-317. doi:10.1038/nn2055 
Stranahan, A. M., Lee, K., Pistell, P. J., Nelson, C. M., Readal, N., Miller, M. G., . . . Mattson, M. P. 
(2008). Accelerated cognitive aging in diabetic rats is prevented by lowering corticosterone 
levels. Neurobiology of Learning and Memory, 90(2), 479-483. 
doi:10.1016/j.nlm.2008.05.005 
Stunkard, A. (2000). Old and new scales for the assessment of body image. Perceptual and Motor 
Skills, 90(3 Pt 1), 930. doi:10.2466/pms.2000.90.3.930 
Stunkard, A. J., Sørensen, T., & Schulsinger, F. (1983). Use of the Danish Adoption Register for the 
study of obesity and thinness. Research Publications - Association for Research in Nervous 
and Mental Disease, 60, 115-120.  
Sukoff Rizzo, S. J., Neal, S. J., Hughes, Z. A., Beyna, M., Rosenzweig-Lipson, S., Moss, S. J., & 
Brandon, N. J. (2012). Evidence for sustained elevation of IL-6 in the CNS as a key 
contributor of depressive-like phenotypes. Transl Psychiatry, 2, e199. 
doi:10.1038/tp.2012.120 
  
103 
 
Suter, M., Calmes, J. M., Paroz, A., & Giusti, V. (2006). A 10-year experience with laparoscopic 
gastric banding for morbid obesity: High long-term complication and failure rates. Obesity 
Surgery, 16(7), 829-835. doi:10.1381/096089206777822359 
Tartaglia, M. C., Narayanan, S., Francis, S. J., Santos, A. C., De Stefano, N., Lapierre, Y., & Arnold, 
D. L. (2004). The relationship between diffuse axonal damage and fatigue in multiple 
sclerosis. Archives of Neurology, 61(2), 201-207. doi:10.1001/archneur.61.2.201 
Taylor, K. L., Hadgkiss, E. J., Jelinek, G. A., Weiland, T. J., Pereira, N. G., Marck, C. H., & van der 
Meer, D. M. (2014). Lifestyle factors, demographics and medications associated with 
depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry, 
14(1), 327. doi:10.1186/s12888-014-0327-3 
Téllez, N., Comabella, M., Julià, E., Río, J., Tintoré, M., Brieva, L., . . . Montalban, X. (2006). 
Fatigue in progressive multiple sclerosis is associated with low levels of 
dehydroepiandrosterone. Multiple Sclerosis, 12(4), 487-494.  
Tettey, P., Simpson, S., Taylor, B., Blizzard, L., Ponsonby, A. L., Dwyer, T., . . . van der Mei, I. 
(2014). Adverse lipid profile is not associated with relapse risk in MS: Results from an 
observational cohort study. Journal of the Neurological Sciences, 340(1-2), 230-232. 
doi:10.1016/j.jns.2014.02.038 
Thompson, P. D. (2003). Exercise and physical activity in the prevention and treatment of 
atherosclerotic cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 
23(8), 1319-1321. doi:10.1161/01.ATV.0000087143.33998.F2 
Thompson, T., Benz, J., Agiesta, J., Brewer, K., Bye, L., Reimer, R., & Junius, D. (2013). Obesity in 
the United States: public perceptions. Retrieved from 
http://www.apnorc.org/PDFs/Obesity/AP-NORC-Obesity-Research-Highlights.pdf 
Thornton, A. E., & Raz, N. (1997). Memory impairment in multiple sclerosis: A quantitative review. 
Neuropsychology, 11(3), 357-366.  
Tinnefeld, M., Treitz, F. H., Haase, C. G., Wilhelm, H., Daum, I., & Faustmann, P. M. (2005). 
Attention and memory dysfunctions in mild multiple sclerosis. European Archives of 
Psychiatry and Clinical Neuroscience, 255(5), 319-326. doi:10.1007/s00406-005-0565-y 
Trojan, D. A., Arnold, D., Collet, J. P., Shapiro, S., Bar-Or, A., Robinson, A., . . . Da Costa, D. 
(2007). Fatigue in multiple sclerosis: Association with disease-related, behavioural and 
psychosocial factors. Multiple Sclerosis, 13(8), 985-995. doi:10.1177/1352458507077175 
Trojano, M., Lucchese, G., Graziano, G., Taylor, B. V., Simpson, S., Jr., Lepore, V., . . . Oreja-
Guevara, C. (2012). Geographical variations in sex ratio trends over time in multiple 
sclerosis. PloS One, 7(10), 1-9. doi:10.1371/journal.pone.0048078 
van Dale, D., & Saris, W. H. (1989). Repetitive weight loss and weight regain: Effects on weight 
reduction, resting metabolic rate, and lipolytic activity before and after exercise and/or diet 
treatment. American Journal of Clinical Nutrition, 49(3), 409-416.  
van Kessel, K., Moss-Morris, R., Willoughby, E., Chalder, T., Johnson, M. H., & Robinson, E. 
(2008). A randomized controlled trial of cognitive behavior therapy for multiple sclerosis 
fatigue. Psychosomatic Medicine, 70(2), 205-213. doi:10.1097/PSY.0b013e3181643065 
Vancampfort, D., De Herdt, A., Vanderlinden, J., Lannoo, M., Soundy, A., Pieters, G., . . . Probst, M. 
(2014). Health related quality of life, physical fitness and physical activity participation in 
treatment-seeking obese persons with and without binge eating disorder. Psychiatry 
Research, 216(1), 97-102. doi:10.1016/j.psychres.2014.01.015 
Vgontzas, A. N., Bixler, E. O., & Chrousos, G. P. (2006). Obesity-related sleepiness and fatigue: The 
role of the stress system and cytokines. Annals of the New York Academy of Sciences, 1083, 
329-344. doi:10.1196/annals.1367.023 
Vgontzas, A. N., Bixler, E. O., Chrousos, G. P., & Pejovic, S. (2008). Obesity and sleep disturbances: 
Meaningful sub-typing of obesity. Archives of Physiology and Biochemistry, 114(4), 224-
236. doi:10.1080/13813450802521507 
  
104 
 
Vighi, G., Marcucci, F., Sensi, L., Di Cara, G., & Frati, F. (2008). Allergy and the gastrointestinal 
system. Clinical and Experimental Immunology, 153 Suppl 1, 3-6. doi:10.1111/j.1365-
2249.2008.03713.x 
Vogeli, C., Shields, A. E., Lee, T. A., Gibson, T. B., Marder, W. D., Weiss, K. B., & Blumenthal, D. 
(2007). Multiple chronic conditions: Prevalence, health consequences, and implications for 
quality, care management, and costs. Journal of General Internal Medicine, 22 Suppl 3, 391-
395. doi:10.1007/s11606-007-0322-1 
Vollmann, M., Scharloo, M., Langguth, B., Kalkouskaya, N., & Salewski, C. (2013). Illness 
representations as mediators of the relationship between dispositional optimism and 
depression in patients with chronic tinnitus: A cross-sectional study. Psychology & Health, 
29(1), 81-93. doi:10.1080/08870446.2013.828294 
Vucic, S., Burke, D., & Kiernan, M. C. (2010). Fatigue in multiple sclerosis: Mechanisms and 
management. Clinical Neurophysiology, 121(6), 809-817. doi:10.1016/j.clinph.2009.12.013 
Waldstein, S. R., & Katzel, L. I. (2006). Interactive relations of central versus total obesity and blood 
pressure to cognitive function. International Journal of Obesity (2005), 30(1), 201-207. 
doi:10.1038/sj.ijo.0803114 
Wang, C., & Coups, E. J. (2010). Causal beliefs about obesity and associated health behaviors: 
Results from a population-based survey. The International Journal of Behavioral Nutrition 
and Physical Activity, 7, 19. doi:10.1186/1479-5868-7-19 
Wang, Y., & Beydoun, M. A. (2007). The obesity epidemic in the United States-gender, age, 
socioeconomic, racial/ethnic, and geographic characteristics: A systematic review and meta-
regression analysis. Epidemiologic Reviews, 29, 6-28. doi:10.1093/epirev/mxm007 
Wang, Y., Beydoun, M. A., Liang, L., Caballero, B., & Kumanyika, S. K. (2008). Will all Americans 
become overweight or obese? Estimating the progression and cost of the US obesity 
epidemic. Obesity (Silver Spring), 16(10), 2323-2330. doi:10.1038/oby.2008.351 
Weiland, T. J., Jelinek, G. A., Marck, C. H., Hadgkiss, E. J., van der Meer, D. M., Pereira, N. G., & 
Taylor, K. L. (2015). Clinically significant fatigue: Prevalence and associated factors in an 
international sample of adults with multiple sclerosis recruited via the internet. PloS One, 
10(2), e0115541. doi:10.1371/journal.pone.0115541 
Weitbrecht, W. U., & Kirchhoff, D. (1995). Long-term prognosis of cerebral infarct in comparison 
with a normal population. Versicherungsmedizin, 47(2), 46-49.  
Wells, K. B., Stewart, A., Hays, R. D., Burnam, M. A., Rogers, W., Daniels, M., . . . Ware, J. (1989). 
The functioning and well-being of depressed patients: Results from the Medical Outcomes 
Study. JAMA, 262(7), 914-919.  
Wilding, J. (2012). Are the causes of obesity primarily environmental? Yes. BMJ, 345, e5843.  
Wingerchuk, D. M., & Rodriguez, M. (2006). Premenstrual multiple sclerosis pseudoexacerbations: 
Role of body temperature and prevention with aspirin. Archives of Neurology, 63(7), 1005-
1008. doi:10.1001/archneur.63.7.1005 
Winter, D. A., Patla, A. E., & Frank, J. S. (1990). Assessment of balance control in humans. Medical 
Progress Through Technology, 16(1-2), 31-51.  
Wright, S. M., & Aronne, L. J. (2012). Causes of obesity. Abdominal Imaging, 37(5), 730-732. 
doi:10.1007/s00261-012-9862-x 
Yim, C. Y., Soczynska, J. K., Kennedy, S. H., Woldeyohannes, H. O., Brietzke, E., & McIntyre, R. S. 
(2012). The effect of overweight/obesity on cognitive function in euthymic individuals with 
bipolar disorder. European Psychiatry, 27(3), 223-228. doi:10.1016/j.eurpsy.2011.02.004 
Zhang, S. M., Willett, W. C., Hernán, M. A., Olek, M. J., & Ascherio, A. (2000). Dietary fat in 
relation to risk of multiple sclerosis among two large cohorts of women. American Journal of 
Epidemiology, 152(11), 1056-1064.  
Zhao, G., Ford, E. S., Dhingra, S., Li, C., Strine, T. W., & Mokdad, A. H. (2009). Depression and 
anxiety among US adults: Associations with body mass index. International Journal of 
Obesity (2005), 33(2), 257-266. doi:10.1038/ijo.2008.268 
  
105 
 
Ziarko, M., Mojs, E., Piasecki, B., & Samborski, W. (2014). The mediating role of dysfunctional 
coping in the relationship between beliefs about the disease and the level of depression in 
patients with rheumatoid arthritis. ScientificWorldJournal, 2014, 585063. 
doi:10.1155/2014/585063 
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica 
Scandinavica, 67(6), 361-370.  
Zorgdrager, A., & De Keyser, J. (1997). Menstrually related worsening of symptoms in multiple 
sclerosis. Journal of the Neurological Sciences, 149(1), 95-97.  
Zorgdrager, A., & De Keyser, J. (2002). The premenstrual period and exacerbations in multiple 
sclerosis. European Neurology, 48(4), 204-206. doi:66166 
 
  
  
106 
 
VITA 
 
Abigail Ness Norouzinia was born in Denver, Colorado  and currently resides in Denver for 
her clinical psychology internship at the Denver VA Medical Center. She has accepted a Postdoctoral 
Fellowship at the Denver VA Medical Center where she plans to specialize in the treatment of PTSD 
and Trauma. She graduated from Colorado State University in 2011 with a Bachelor of Science 
degree in Psychology. Abby would like to thank her research mentor, Jared Bruce, for his continual 
support, patience, and mentorship throughout graduate school. She would also like to acknowledge 
her parents and husband for their encouragement and support to pursue her dream of becoming a 
clinical psychologist.  
 
